I. Introduction
Receptors, transporters, ion channels, and enzymes in the central nervous system (CNS 1 ) exhibit high heterogeneity in terms of structure, function, and pharmacology. These protein isoforms, particularly neurotransmitter receptors, have traditionally been classified by pharmacological differences in the affinities of antagonists/inhibitors. The use of techniques of functional pharmacology, together with the availability of selective ligands, has led to the identification of multiple receptive sites in which the same neurotransmitter binds to elicit various responses. Studies of molecular biology have confirmed the existence of receptor types and subtypes within a single species by showing that pharmacological differences reflect differences in primary structure. It has subsequently become apparent that functionally equivalent receptors between species can display distinct pharmacological profiles and molecular biologists have identified key amino acids responsible for imparting ligand specificity. Clearly, this high receptor heterogeneity increases the likelihood of interspecies differences, thus making of unique importance studies on human brain functional proteins.
Mechanisms by which synaptic strength is modified play critical roles in neurotransmission. In the CNS, modification of the strength of synapses can be produced through neurotransmitters/neuromodulators released by neurons and glia. A classic mechanism by which the strength of synapses can be modulated involves the activation of receptors localized on neuronal axon terminals and termed presynaptic receptors (Starke et al., 1989; Bonanno and Raiteri, 1993; Langer, 1993; Miller, 1998; Raiteri, 2001) . Presynaptic receptors can be activated by transmitters/modulators released by the terminals on which the receptors are localized (presynaptic autoreceptors) or by transmitters/modulators originating from neighboring structures (presynaptic heteroreceptors). Although the classic presynaptic modulatory systems involve metabotropic G protein-coupled receptors (GPCRs), presynaptic ionotropic receptors also can modify transmitter release [see Engelman and MacDermott (2004) for a review].
As to neurotransmitter transporters, their roles in brain physiology and pathology are only understood in part. These proteins represent highly sophisticated systems able to play more refined roles than simple transmitter (re)uptake. All known transmitter transporters can, under some conditions, mediate transmitter release directly from the cytosol (Attwell et al., 1993; Levi and Raiteri, 1993) . Transporters may regulate the time course of synaptic events by modifying the extent of activation of receptors and the level of their desensitization (Seal and Amara, 1999; Sims and Robinson, 1999) . Transporters for different transmitters can coexist and interact with each other on the same neuron [see Raiteri et al. (2002a) for a review]. Interactions between transporters and presynaptic receptors, as well as trafficking of transporters between the plasma membrane and intracellular pools, have been described previously (Reith, 2002) .
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The present article is essentially focused on functional studies performed with fresh human brain tissue not considered in my previous review (Raiteri, 1994) . Data from laboratory animal experiments are here discussed only in comparative terms to help in the choice of the animal species possibly representing appropriate models to be used in preclinical studies.
II. Cholinergic Receptors
Muscarinic receptors and their subtypes were the first cholinergic receptors to be functionally identified and characterized in human brain. In particular, a number of studies were published in the early 1990s dealing with muscarinic autoreceptors mediating inhibition of acetylcholine (ACh) release from human neocortex tissues (Feuerstein et al., 1990 (Feuerstein et al., , 1992 Marchi et al., 1990; Beani et al., 1992) . These works have already been considered in my previous review (Raiteri, 1994) . Curiously, to my knowledge, no new reports of functional studies on human brain muscarinic receptors have appeared in the last decade. In contrast, there has been increasing interest in the identification and pharmacological characterization of native nicotinic ACh receptors (nAChRs) through functional studies with samples of human brain obtained in neurosurgery.
Nicotine produces several central effects, some of which seem to be beneficial, e.g., increased alertness, reduced anxiety, analgesia, and facilitation of cognitive processes. Subtypes of the nAChR have been proposed as potential targets for drugs to be used in Alzheimer's disease and in other pathological conditions (Lloyd and Williams, 2000; Paterson and Nordberg, 2000) ; the knowledge of their function, structural subunit composition, and pharmacology in the human CNS is therefore of critical importance for the development of mechanism-based therapeutic approaches.
A. Norepinephrine Release Regulation by Nicotinic Receptors
Nicotinic receptors are largely localized on presynaptic axon terminals where they mediate regulation of neurotransmitter release (Wonnacott, 1997) . Nicotine was found to cause norepinephrine (NE) release from human neocortex slices through activation of mecamylamine-sensitive mechanisms (Pittaluga et al., 1999) . Although, based on experiments with rat brain synaptosomes, nAChRs mediating an increase in NE release can be thought to exist on noradrenergic nerve terminals (Clarke and Reuben, 1996; Luo et al., 1998; Vizi, 1998; Risso et al., 2004) , to what extent nicotinic agonists directly act at noradrenergic terminals in human cortex to evoke NE release remains to be established; in fact, the release of NE elicited by nicotine in human cortical slices was in part prevented by glutamate N-methyl-D-aspartate (NMDA) receptor antagonists, suggesting an indirect mechanism whereby nicotine can provoke glutamate release onto NMDA receptors mediating release of NE (Pittaluga et al., 1999) . Nicotine has indeed been reported to increase glutamate release in various animal preparations (Gray et al., 1996; Fedele et al., 1998) as well as in human cerebrocortex (Marchi et al., 2002b; see below) .
The release of NE evoked by nicotine from human cerebrocortical slices prepared from specimens removed during neurosurgery for intractable severe epilepsy was external Ca 2ϩ -dependent and attenuated by the N-type voltage-sensitive calcium channel (VSCC) blocker -conotoxin GVIA (Woo et al., 2002) , suggesting activation of VSCCs following depolarization provoked by nicotine. As the nAChRs involved are insensitive to ␣-bungarotoxin, the authors tend to exclude the theory that ␣7 subunit-containing nAChRs play a relevant role, although the use of some other selective antagonist would be advisable. Interestingly, Woo et al. (2002) found that the nicotine-evoked release of NE was prevented by nitric-oxide synthase inhibitors, indicating the involvement of nitric oxide (NO). Moreover, the nicotine effect was attenuated by guanylyl cyclase inhibitors and potentiated by the phosphodiesterase inhibitor zaprinast, consistent with the involvement of cyclic GMP. Although the authors, based on a few results with glutamate receptor antagonists, proposed that endogenous glutamate does not play a role in the nicotine effect, the stimulation by nicotine of the NO/cyclic GMP pathway would seem compatible with the idea that, in human neocortical slices, nicotine causes release of glutamate onto NMDA receptors mediating both NO production (Maura et al., 2000) and NE release (Fink et al., 1992a) .
Nicotinic receptors mediating NE release have recently been characterized by Amtage et al. (2004) antagonists, consistent with the findings and interpretation given by Pittaluga et al. (1999) that only part of the nAChRs involved in NE release are located on noradrenergic neurons, whereas some are on glutamatergic neurons from which glutamate is released onto noradrenergic terminals. Of note, Amtage et al. (2004) report that nicotinic agonists seem unable to evoke release of [ 3 H]NE from rat neocortical slices, which would make it inappropriate to use the rat cortex as a model to screen for NE release-enhancing nicotinic receptor agonists.
In their work Amtage et al. (2004) characterized pharmacologically the subunit composition of the nAChRsmediating enhancement of NE release in the human neocortex by using a number of selective nAChR antagonists. The nicotine-evoked [ 3 H]NE release was sensitive to ␣-conotoxin MII, an antagonist that selectively blocks ␣3␤2-and ␣6-containing nAChRs. On the other hand, ␣-conotoxin AuIB, a selective ␣3␤4-subtype antagonist, failed to block the nicotine effect, thus excluding the involvement of ␣3␤4 subunit-containing nAChRs, in contrast to some observations on rat brain tissue (Vizi and Lendvai, 1999; Anderson et al., 2000) . Surprisingly, Amtage et al. (2004) found no evidence for the presence of nicotinic autoreceptors on cholinergic terminals in both human and rat neocortex. The authors admit that their "conclusion is in contrast to previous studies with mice and rats which suggest the occurrence of presynaptic nicotinic autoreceptors in the rodent brain." But the negative findings of Amtage et al. (2004) particularly contrast with results by Marchi et al. (2002b) showing the presence of release-enhancing nicotinic autoreceptors on cholinergic axon terminals isolated from human neocortical tissue (see below). The reasons for these discrepancies may be manifold, although it seems that the use of human (or rat) slices prevents in some way the identification of presynaptic receptors that can be clearly observed in superfused isolated axon terminal preparations.
B. Nicotinic ␣7 Receptors and Glutamate Release
The existence of presynaptic nAChRs able to mediate glutamate release had been suggested by different authors, based on electrophysiological and neurochemical studies in the laboratory animals (McGehee and Role, 1995; Gray et al., 1996; Radcliffe and Dani, 1998) . However, direct demonstration that release-regulating nAChRs exist on glutamatergic axon terminals both in rat and human brain was obtained only recently (Marchi et al., 2002b) . Experiments performed with synaptosomes prepared from fresh specimens of human cerebral cortex showed that nAChR agonists evoked release of glutamate, an effect prevented by ␣-bungarotoxin or by methyllycaconitine at concentrations compatible with their selective blockade of nAChRs containing ␣7 subunits. Similar results have been obtained using synaptosomes from the rat corpus striatum (Marchi et al., 2002b) and, more recently, the rat hippocampus and cortex (unpublished results). It may be added that the ␣7 nAChRs involved are presynaptic heteroreceptors localized on glutamatergic axon terminals because the superfusion system used only shows release modulations of a given transmitter when they are consequent to direct actions on the synaptosomes releasing that transmitter, whereas indirect effects are prevented (see Raiteri and Raiteri, 2000) .
The ␣7 nicotinic receptors able to mediate glutamate release in the human cerebral cortex might be involved in the cognition-enhancing activity of nicotine (see Levin and Simon, 1998) . The pharmacological similarity between human and rat nicotinic heteroreceptors mediating potentiation of glutamate release suggests that the rodent receptor could represent a useful model in the development of new ␣7 nAChR ligands.
C. Nicotinic Autoreceptors
When isolated human neocortex nerve endings, prelabeled with [ 3 H]choline, were exposed in superfusion to nicotine or to ACh (in the presence of atropine to block inhibitory muscarinic autoreceptors), an increase in the release of [ 3 H]ACh was observed (Marchi et al., 2002b) . The releasing effect of ACh ϩ atropine was insensitive to ␣-bungarotoxin or to methyllycaconitine, thus excluding the involvement of ␣7 nAChRs. The following considerations support the view that these autoreceptors mediating positive feedback regulation of ACh release are ␣4␤2 nAChRs as previously suggested for the rat nicotinic autoreceptor (Wilkie et al., 1996) : 1) dihydro-␤-erythroidine, which completely blocked the effect of ACh at the autoreceptor, has been reported to be reasonably selective for the ␣4␤2 subtype (Albuquerque et al., 2000) ; 2) the EC 50 values for (Ϫ)-nicotine (1 M) and ACh (5 M) in activating human autoreceptors are in keeping with those found at ␣4␤2 receptors heterologously expressed in different systems (McGehee and Role, 1995; Gopalakrishnan et al., 1997) ; 3) nicotine was significantly more potent on human ␣4␤2 than on human ␣4␤4, ␣2␤4,␣3␤2, and ␣3␤4 receptors (Stauderman et al., 1998) ; 4) ␣4␤2 nAChRs constitute the major subtype lost in the cortex and hippocampus of Alzheimer's patients (Warpman and Nordberg, 1995) , compatible with their presence on degenerating cholinergic axon terminals.
It seems important that the nicotinic autoreceptors localized on cholinergic terminals represent distinct nAChRs compared with the nicotinic heteroreceptors present on glutamatergic nerve endings: these two native subtypes of nAChR have different neuronal localization, subunit composition, function, and pharmacology (Marchi et al., 2002b) . The pharmacological diversity offers a number of opportunities in terms of therapeutic intervention: autoreceptor (␣4␤2) agonists and heteroreceptor (␣7) agonists are expected to reinforce the acetylcholine-glutamate pathway by increasing, respectively, ACh release and glutamate release. 166 RAITERI Moreover, the pharmacology of these native human nAChRs seems very similar to that of the corresponding native rat receptors. Thus, monitoring glutamate and ACh release from rat brain synaptosomes may represent a convenient approach to functionally evaluate novel ligands at ␣7-or ␣4␤2-containing nAChRs.
III. Adrenergic Receptors
The existence of several types and subtypes of adrenergic receptors and the consequent possibility of species differences would require extensive characterization of human adrenoceptors before appropriate animal models are chosen. However, functional studies of adrenergic receptors in human brain have focused exclusively on ␣ 2 -receptors regulating neurotransmitter release. Of these studies, those describing ␣ 2 -adrenergic regulation of ACh and glutamate release (Beani et al., 1992) , of GABA release (Ferraro et al., 1993) and of serotonin release Feuerstein et al., 1993 ) from human cerebral cortex tissues have already been considered in my previous review (Raiteri, 1994) .
A. Norepinephrine Release Regulation through Autoreceptors
Similarly to what had been shown in several laboratory animal species [see Starke et al. (1989) for a review], human neocortex autoreceptors exhibit an ␣ 2 -adrenoceptor pharmacology . Experiments with human neocortical slices prelabeled with [
3 H]NE and stimulated electrically showed that the Ca 2ϩ -dependent and tetrodotoxin-sensitive release of the catecholamine was inhibited by clonidine (an ␣ 2 agonist) and by oxymetazoline (an ␣ 2 agonist that displays high-affinity for ␣ 2A /␣ 2D receptors and low affinity for the ␣ 2B /␣ 2C subtypes). Moreover, the human autoreceptors were insensitive to prazosin and to ARC239 (antagonists that exhibit high affinity for ␣ 2B and ␣ 2C adrenoceptors but low affinity for ␣ 2A /␣ 2D subtypes). Based on these results, obtained with the few selective ligands available in the early 1990s, it was concluded that the presynaptic ␣ 2 -autoreceptors that modulate NE release in the human neocortex are not ␣ 2B /␣ 2C but are either ␣ 2A or ␣ 2D .
It was subsequently established that ␣ 2A -and ␣ 2D -adrenoceptors are species orthologs, of which only one occurs in a given species and that humans possess the ␣ 2A version, whereas rodents possess the ␣ 2D version (Sastre and García-Sevilla, 1994; Bylund, 1995) . Human neocortical ␣ 2 -autoreceptors therefore belong to the ␣ 2A subtype of the adrenoceptor.
In 2000, Feuerstein et al. reinvestigated the subtype to which the ␣ 2 -autoreceptors belong in the human neocortex by using nine antagonists, including prazosin and ARC239, of which the authors could evaluate the dissociation constants (pK B values) at the autoreceptors. The pK B values of prazosin and ARC239 were the lowest (more than 2 orders of magnitude lower than that of rauwolscine), in keeping with the previous findings of Raiteri et al. (1992) showing insensitivity of the human autoreceptors to the two compounds. Compared with binding or functional results from the literature, the pK B values of the nine antagonists tested by Feuerstein et al. (2000) correlated best with the antagonist affinities at ␣ 2A binding sites, leading the authors to the definitive conclusion that the human neocortex presynaptic autoreceptors are ␣ 2A . In considering that the rodent release-regulating ␣ 2 -autoreceptors belong to the ␣ 2D subtype (Limberger et al., 1995) , whereas the rabbit and pig cortical autoreceptors are ␣ 2A (Limberger et al., 1995; Trendelenburg et al., 1997) , it seems appropriate to use brain cortical tissues from guinea pigs or pigs as human autoreceptor models.
IV. Dopamine Receptors and Transporters

A. Dopamine Autoreceptors
The existence of release-regulating dopamine (DA) autoreceptors in human brain was investigated in slices from fresh specimens of human neocortex that were labeled with [ 3 H]DA and stimulated electrically (Fedele et al., 1993) . Whereas the selective DA-1 receptor agonist SKF38393 did not affect the electrically evoked release of DA, quinpirole, an agonist at the receptors of the DA-2 family, with preference for the DA-2/DA-3 subtypes, inhibited the evoked release in a concentrationdependent manner. Quinpirole was antagonized by (Ϫ)-sulpiride, a DA-2 receptor antagonist with preference for the DA-2/DA-3 subtypes.
In a subsequent work, investigated the pharmacological profile of DA autoreceptors in human neocortex further, to establish the subtype (DA-2, DA-3, or DA-4) to which the receptors belong. The quinpirole inhibition of the electrically evoked DA release was unaffected by the selective DA-4 receptor antagonist L-745,870 and by the selective DA-3 receptor antagonist S14297, leading to the conclusion that, in human neocortex, the release of DA in the terminal region of midbrain dopaminergic neurons is regulated through autoreceptors of the DA-2 subtype.
To identify a readily accessible model to be used in the development of selective DA-2 receptor ligands, compared the results from human neocortical slices with those obtained in three animal systems: rat neocortical slices, rat striatal slices, and rat mesencephalic neuronal cultures, from which DA release was electrically stimulated. Results from rat striatal slices, mesencephalic neurons and human neocortical slices were superimposable, whereas quantitative differences emerged in the case of rat cortical slices.
B. Drugs of Abuse and Dopamine Release
Drug addiction is believed to result from the reinforcing properties of drugs of abuse on central reward sys-FUNCTIONAL PHARMACOLOGY IN HUMAN BRAIN tems, in particular on mesolimbic DA pathways (Di Chiara and Imperato, 1988; Koob et al., 1998) . Although microdialysis experiments in rodents indicate that ethanol can evoke DA release in the nucleus accumbens (Di Chiara and Imperato, 1988; Rossetti et al., 1992; Weiss et al., 1993) , studies on the effect of alcohol consumption by humans on dopaminergic transmission are very rare. Boileau et al. (2003) Laruelle (2000) for a review]. Boileau et al. (2003) observed a significant reduction in [
11 C]raclopride binding potential bilaterally in the ventral striatum/nucleus accumbens, indicative of increased extracellular DA. The above technique had previously been used in humans to evaluate extracellular DA augmentation in response to various psychostimulants (Carson et al., 1997; Schlaepfer et al., 1997; Drevets et al., 2001; Volkow et al., 2001; Leyton et al., 2002; Martinez et al., 2003) . Altogether, these findings support the idea that mesolimbic dopaminergic activation is a common property of abused drugs in humans.
C. Drugs of Abuse and Dopamine Transporters
Dopamine transporters (DATs) are targets for cocaine and other psychostimulants (Amara and Kuhar, 1993) . In particular, cocaine potentiates dopaminergic transmission by blocking the reuptake of DA, leading to elevations in the synaptic level of the neurotransmitter. In vivo imaging studies in humans and in vitro binding studies in postmortem human brain have shown that chronic cocaine abuse results in an increase in DAT binding site density in the nucleus accumbens [see Mash et al. (2002) for references]. These data do not indicate, however, whether the increase in DAT binding sites reflects and increase in the function of DA transporters. Mash et al. (2002) measured uptake of [ 3 H]DA in metabolically active synaptosomes isolated from cryoprotected human brain specimens. The uptake of DA was elevated 2-fold in the ventral striatum from cocaine users compared with age-matched drug-free control subjects. This seems to be the first demonstration of adaptations in DA uptake in postmortem human brain. Based on the results, it is likely that chronic cocaine use, by causing an increase in DAT levels, results in a reduced amount of synaptic DA available to stimulate postsynaptic receptors. According to Mash et al. (2002) , "the need to maintain homeostasis within central dopaminergic systems may be one of the factors that drives the compulsive use of cocaine."
V. Serotoninergic Receptors
Pharmacological studies as well as molecular cloning of 5-hydroxytryptamine (5-HT; serotonin) receptors have revealed high receptor heterogeneity. Seven major types of the 5-HT receptor have been identified and termed 5-HT 1 to 5-HT 7 . Most of these receptor types are heterogeneous and occur as subtypes. Species homologs of the same receptor subtype may exist which, despite high structural homology, may display pronounced pharmacological differences (Hoyer and Middlemiss, 1989; Hoyer et al., 1994; Martin and Humphrey, 1994; Hartig et al., 1996) .
Among -dependent and could be inhibited by exogenous 5-HT. The inhibition was prevented by methiothepin, a broad spectrum 5-HT receptor antagonist (Schlicker et al., 1985) . These results show that release-inhibiting presynaptic 5-HT autoreceptors, previously found to be present in the rat brain (Cerrito and Raiteri, 1979; Göthert and Weinheimer, 1979) , also exist in the human brain.
Based on pharmacological studies, rat brain 5-HT autoreceptors had originally been classified as 5-HT 1B subtype (Engel et al., 1986; Maura et al., 1986) . However, 5-HT 1B binding sites could not be detected in the human brain ; therefore, it was expected that the human autoreceptors would have been pharmacologically different from those in the rat brain.
A subtype of the 5-HT binding site, termed 5-HT 1D , was then identified in human brain (Herrick-Davis et al., 1988; Hoyer et al., 1988) as well as in the brain of other species lacking the 5-HT 1B site (Bruinvels et al., 1992) and found to display a regional distribution similar to that of the 5-HT 1B site in rodents (Waeber et al., 1989) . On the basis of this new information, receptors regulating the release of [ 3 H]5-HT from human neocortex slices (Galzin et al., 1992) and human neocortex synaptosomes (Maura et al., 1993) were proposed to belong to the 5-HT 1D subtype.
Subsequent cloning studies revealed that 5-HT 1D receptors are heterogeneous: two members of the subfamily, which were called 5-HT 1D␣ and 5-HT 1D␤ , were identified in the human brain . Interestingly, replacement by site-directed mutagenesis of the threonine residue present at position 355 in the 168 RAITERI human 5-HT 1D␤ receptor with the corresponding asparagine found in rodent 5-HT 1B receptors was found to render the pharmacology of the receptors, originally quite different, essentially identical (Oksenberg et al., 1992; Parker et al., 1993) . The human 5-HT 1D␤ and the rodent 5-HT 1B receptors are encoded by a corresponding gene and may have the same biological functions in the two species. Having assumed this, it was proposed that the human autoreceptor be classified as 5-HT 1D␤ (now termed h5-HT 1B ) (Maura et al., 1993; Fink et al., 1995) .
A clear confirmation that, in human cerebral cortex, the terminal 5-HT autoreceptor is of the h5-HT 1B subtype came from experiments with an h5-HT 1B selective ligand, SB-236057, which was shown to block the human terminal autoreceptor in a release study with human neocortex slices stimulated electrically (Middlemiss et al., 1999) .
The available literature shows that h5-HT 1B receptors differ pharmacologically from the rodent r5-HT 1B receptors (Oksenberg et al., 1992; Parker et al., 1993) . Therefore, the rodent autoreceptor cannot be useful as a model for the human counterpart. Other animal species, including guinea pig, pig, and rabbit, possess 5-HT autoreceptors that pharmacologically resemble the h5-HT 1B subtype and may represent appropriate models for the human 5-HT autoreceptor.
B. Glutamate Release and Modulation by Human 5-Hydroxytryptamine 1D Receptors
Animal studies suggest that 5-HT can interact with glutamate through multiple receptors to inhibit excitatory transmission in the CNS [see Maura et al. (1998) and references therein]. Because excessive glutamate release has been implicated in a number of pathophysiological conditions, understanding how the release of the excitatory transmitter can be regulated in the human CNS may lead to novel therapeutic avenues.
Several years ago we found that the release of glutamate from rat cerebellar synaptosomes could be potently inhibited through the activation of an unknown subtype of the 5-HT 1 receptor that we suggested be named 5-HT 1D . When the rat 5-HT 1D (now termed r5-HT 1D ) was cloned, it was proposed to represent the species homolog of the human 5-HT 1D (now h5-HT 1D ) receptor (Hamblin and Metcalf, 1991; Hartig et al., 1996) .
To investigate whether 5-HT could directly modulate the release of glutamate in human brain, the efflux of glutamic acid and its modulation by 5-HT were studied in synaptosomal preparations from fresh neocortical samples obtained from patients undergoing neurosurgery to reach deeply sited tumors. Depolarization with high-K ϩ elicited Ca 2ϩ -dependent release of endogenous glutamate, which was inhibited by exogenous 5-HT and by the 5-HT 1B/1D selective agonist sumatriptan. The agonist effects were blocked by concentrations of ketanserin known to antagonize preferentially the h5-HT 1D versus the h5-HT 1B receptors (Maura et al., 1998) .
These results represent the first functional characterization of a 5-HT 1D receptor in the adult human brain. In considering that the human terminal autoreceptor is h5-HT 1B , the emerging pharmacological differences between h5-HT 1B auto-and h5-HT 1D heteroreceptors (see below) may lead to the development of novel therapeutic agents. Inhibition by 5-HT of glutamatergic transmission may be useful in a variety of pathological conditions including epilepsy [see Clough et al. (1996) and references therein], ischemia (Marcoli et al., 2004 ) (see also section XIII.C.) and depression [see Bonanno et al. (2005) and references therein].
C. Pharmacological Diversity between Human 5-Hydroxytryptamine 1B and Human 5-Hydroxytryptamine 1D Receptors
h5-HT 1B and h5-HT 1D receptors have been reported to have relatively low (63%) overall amino acid homology; in contrast, for a series of 19 structurally diverse compounds, the two cloned human receptors were originally found to be nearly indistinguishable in their binding affinities Weinshank et al., 1992) . This view, based on radioligand binding experiments with cell lines expressing the cloned h5-HT 1B and h5-HT 1D receptors, is no longer tenable in the light of the functional studies of native receptors carried out with human neocortex synaptosomes (Marcoli et al., 1999) . This study analyzed the pharmacological profiles of the presynaptic h5-HT 1B autoreceptors regulating the depolarization-evoked release of [ 3 H]5-HT and of the presynaptic h5-HT 1D heteroreceptors regulating the depolarization-evoked release of endogenous glutamate from human cerebral cortex synaptosomes. The nerve terminals were exposed in superfusion to eight serotonergic ligands during depolarization. Whereas two compounds, sumatriptan and methiothepin, behaved similarly at the auto-and at the heteroreceptors, the behavior of the other six compounds at the h5-HT 1B autoreceptor differed strikingly from that at the h5-HT 1D heteroreceptor (Table 1) . Of note, some drugs known as 5-HT receptor antagonists, in particular metergoline and GR127935, behaved as blockers at the autoreceptors but exhibited potent intrinsic activity at the heteroreceptors, thus strongly inhibiting glutamate release. To conclude, our functional studies of native h5-HT 1B and h5-HT 1D receptors in the cerebral cortex show that the two receptors, originally reported to be pharmacologically identical , exhibit in fact a strikingly different pharmacology. The finding that compounds known to behave as pure 5-HT receptor antagonists in experiments with laboratory animals become full agonists at native 5-HT 1D receptors in human brain may be due to several reasons, including the exsistence of a high reserve of h5-HT 1D receptors. Whatever the explanation, considering the variability of the results obtained with cell systems expressing recombinant receptors, as well as the species variations in ligand affinities previously observed (see Zgombick et al., 1997) , it is evident that functional studies with native human receptors remain of unique importance.
The pharmacological diversity of human 5-HT 1B and 5-HT 1D receptors augurs well for the potential development of receptor-selective drugs. In particular, the clear differences existing between release-regulating h5-HT 1B terminal autoreceptors and h5-HT 1D terminal heteroreceptors in human brain open the possibility for development of drugs that are selective autoreceptor antagonists or heteroreceptor agonists or both and that may represent novel mechanism-based therapeutic approaches potentially useful in conditions characterized by defective serotonergic transmission or/and excessive glutamatergic transmission including depression, epilepsy, and neurodegenerative diseases. 3 H]GABA, whereas methiothepin, a broad spectrum 5-HT receptor antagonist, prevented the sumatriptan effect. The use of slices does not permit a precise localization of the receptor, whether on the soma/dendrites or the terminals of GABA neurons or on both. As to the subtype of the 5-receptor involved, the authors proposed the 5-HT 1D as the most likely. As discussed above, in 1996, the human 5-HT 1D nomenclature comprised two receptors termed 5-HT 1D␣ and 5-HT 1D␤ (now h5-HT 1D and h5-HT 1B ); accordingly Feuerstein et al. (1996a) proposed that the 5-HT 1D receptor regulating GABA release in human neocortex was the 5-HT 1D␣ or 5-HT 1D␤ subtype. The pharmacology of this receptor could be characterized more precisely by using the tools now available (see Marcoli et al., 1999) .
D. GABA Release and Modulation by 5-Hydroxytryptamine
Interestingly, in rabbit neocortex slices, the release of GABA could not be inhibited by sumatriptan. In addition, 5-carboxamidotryptamine, a broad spectrum 5-HT 1 agonist, was unable to affect the release of GABA evoked by electrical stimulation of rabbit neocortex, suggesting that receptors of the 5-HT 1 type regulating GABA release may not exist on GABAergic neurons of the rabbit neocortex.
E. Serotonin Inhibition of the N-Methyl-D-aspartate Receptor/Nitric Oxide/Cyclic GMP Pathway
The NMDA receptor/NO/cyclic GMP pathway and its possible modulation by 5-HT were studied in slices of human neocortex (Maura et al., 2000) . Exposure of slices to NMDA caused cyclic GMP elevation, which was blocked by NO synthase and guanylate cyclase inhibitors. The NMDA effect was potently prevented by 5-HT or by the 5-HT 2 receptor agonist (Ϯ)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane. Further pharmacological analysis with 5-HT 2A , 5-HT 2B , and 5-HT 2C receptor antagonists and the novel selective 5-HT 2C agonist Ro60-0175 showed that the 5-HT 2 receptor involved belongs to the 5-HT 2C subtype.
The 5-HT 2C receptor is not the only serotonergic receptor involved, however. In fact, the 5-HT 1A agonist 8-OH-DPAT inhibited the NMDA-evoked cyclic GMP response, an effect blocked by selective 5-HT 1A antagonists.
The work by Maura et al. (2000) also described the ability of the antidepressant trazodone to inhibit the NMDA receptor/NO/cyclic GMP pathway through the activation of 5-HT 2C receptors. The mechanism of action of trazodone as an antidepressant is not well understood, although a number of authors have proposed interactions with the serotonergic system [see Maura et al. (2000) for references]. The finding that trazodone, at concentrations compatible with those reached during antidepressant treatment, inhibited the NMDA receptor-mediated production of NO and cyclic GMP in human neocortical slices through receptors of the 5-HT 2C subtype suggests that activation of 5-HT 2C receptors could be relevant to the antidepressant activity of trazodone and, possibly, of selective serotonin reuptake inhibitors that also indirectly activate 5-HT 2C receptors. It should be noted that antidepressants were reported to produce adaptive changes, generally inhibitory, of NMDA receptor functions (Leonard, 1997; Nowak et al., 1998) .
Altogether, the results available from experiments with fresh human brain tissues indicate that 5-HT is a major inhibitory agent of glutamatergic transmission in the human cerebral cortex able to act at multiple sites ( Fig. 1) . Not only can serotonin inhibit the evoked release of glutamate from nerve terminals by acting at presynaptic h5-HT 1D receptors (Maura et al., 1998) ; it 170 RAITERI also can inhibit events triggered by glutamate release, i.e. the NMDA receptor/NO/cyclic GMP pathway, by acting at postsynaptic receptors of the 5-HT 2C and 5-HT 1A subtype. Agonists at human 5-HT 1D , 5-HT 2C , and 5-HT 1A receptors or antagonists at 5-HT 1B autoreceptors, deserve attention as potentially useful drugs in neuropathologies with underlying defective serotonergic or excessive glutamatergic transmission.
VI. GABA Receptors
Ionotropic GABA A receptors have been the object of a number of functional studies with human brain tissue removed to treat drug-resistant epilepsies (see section XII.A.1.). As to receptors of the GABA B type, several reports deal with these metabotropic GABA receptors in human brain and are mainly focused on the existence of GABA B receptor subtypes [see Bonanno and Raiteri (1993) and Bowery et al. (2002) for reviews].
A. GABA B Receptor Subtypes: Pharmacological Evidence 1. GABA B Autoreceptors. The release of GABA from human cerebral cortex synaptosomes depolarized in superfusion with high-K ϩ was inhibited by the GABA B receptor agonist (Ϫ)-baclofen, but not by the GABA A agonist muscimol, suggesting the presence of releaseregulating GABA B autoreceptors in human neocortex GABAergic terminals (Bonanno et al., 1989) . The existence of GABA B autoreceptors in human CNS was confirmed when the introduction of potent, selective GABA B receptor antagonists (Froestl et al., 1995) facilitated studies of GABA B receptors. In particular, the human GABA B autoreceptor was characterized using three antagonists: phaclofen, CGP35348 and CGP52432 (Fassio et al., 1994) . The effect of (Ϫ)-baclofen on the evoked release of GABA from human neocortex synaptosomes was differentially reduced by the three antagonists: CGP52432 was by far the most potent (IC 50 ϭ 0.09 M); phaclofen was much less potent (IC 50 ϭ 70 M); CGP35348 was ineffective up to 100 M. These results parallel those previously obtained with the neocortex of the rat Lanza et al., 1993) , indicating that human and rat cortical autoreceptors are pharmacologically very similar (Table 2) .
2. GABA B Heteroreceptors Regulating Neuropeptide Release. Human neocortex synaptosomes released cholecystokinin-like immunoreactivity (CCK-LI) and somatostatin-like immunoreactivity (SRIF-LI) in a Ca 2ϩ -dependent manner when depolarized in superfusion with high-K ϩ . The GABA B receptor agonist (Ϫ)-baclofen inhibited both the evoked release of CCK-LI and SRIF-LI. The effect of (Ϫ)-baclofen was mimicked by CGP47656 and blocked by CGP35348 or CGP52432. Interestingly, in experiments of GABA release, CGP47656 behaved as an antagonist at the GABA B autoreceptors Raiteri et al., 1996) . Together, these results indicate that 1) CCK-and SRIF-releasing terminals in human neocortex possess release-inhibiting GABA B heteroreceptors; 2) these receptors differ pharmacologically from the human GABA B autoreceptors since the latter are CGP35348-insensitive (Fassio et al., 1994) and can be blocked by CGP47656; 3) human heteroreceptors regulating CCK and SRIF release seem to be pharmacologically similar to the corresponding receptors found in rats (Gemignani et al., 1994 ; Table 2 ). Cholecystokinin has been implicated in anxiety (Woodruff and Hughes, 1991; Harro et al., 1993) ; thus, the finding that inhibitory GABA B heteroreceptors present on CCK-releasing terminals differ pharmacologically from the GABA B autoreceptors mediating inhibition of GABA release suggests that GABA B heteroreceptor-selective agonists may have therapeutic potential as novel anxiolytics. As to the somatostatinergic system, reduced release of SRIF seems to play a role in cognitive impairments typical of Alzheimer's disease (Gabriel et al., 1993) or accompanying other pathologies; selective GABA B heteroreceptor antagonists could lead to increased SRIF release and consequently to cognitive improvement (see below).
A GABA B receptor antagonist, CGP36742, had been reported to improve the performances of mice, rats, and monkeys in tests covering diverse manifestations of learning and memory (Mondadori et al., 1993; Froestl et al., 1995) . We examined the ability of CGP36742 to block release-regulating GABA B receptors. In particular, CGP36742 was tested against the inhibition of the depolarization-evoked release of GABA, glutamate, CCK, and SRIF produced by (Ϫ)-baclofen in rat and human neocortex axon terminals . It was found ( Table 2 ) that CGP36742 potently antagonized the inhibition by (Ϫ)-baclofen of the release of SRIF from both rat (IC 50 ϭ 0.14 M) and human (IC 50 ϳ 5 M) neocortex synaptosomes. In contrast, the effects of (Ϫ)-baclofen on GABA, glutamate, and cholecystokinin release were insensitive to CGP36742 at concentrations up to 100 M. CGP36742 is the first GABA B receptor antagonist displaying great selectivity for the GABA B presynaptic receptors regulating SRIF release. Considering the implication of the neuropeptide in cognitive processes, disinhibition of SRIF release with activation of SRIF receptors may represent one of the mechanisms involved in the behavioral activity of CGP36742. In the rat brain, the CGP36742-induced somatostatin (sst5) receptor activation was found to facilitate the function of NMDA receptors (Pittaluga et al., 2000 (Pittaluga et al., , 2001a , which are known to play a primary role in cognitive processes. If humans respond as rats, CGP36742 (now termed SGS742) could act according to the scheme shown in Fig.  2 Interestingly, CGP36742/SGS742 is the first GABA B receptor antagonist entered into clinical trials. In a phase II double-blind, placebo-controlled study in 110 patients with mild cognitive impairment, oral adminis-FIG. 2. Schematic representation of the neurotransmitter interactions that may underlie the cognitive enhancing activity of CGP36742 (now termed SGS742). GABA and somatostatin (SRIF) are often colocalized in interneurons, although purely GABAergic terminals (not shown) also exist. Glutamate (GLU; red dots) evokes release of norepinephrine (NE; brown dots), GABA (blue dots), and SRIF (green dots) by activating ionotropic NMDA/AMPA receptors located on the respective axon terminals. GABA can inhibit its own release and SRIF release through different GABA B receptor subtypes. CGP36742 (SGS742) binds with high affinity to the GABA B heteroreceptor (violet) modulating SRIF release but with very low affinity to the GABA B autoreceptor (blue) modulating GABA release . SRIF positively modulates NE release by activating sst 5 receptors (green) colocalized with NMDA receptors on noradrenergic terminals. When NMDA is added to slices, GABA is released and inhibits the release of SRIF. CGP36742 (SGS742) prevents this GABAergic inhibition, allowing the neuropeptide to reach the sst 5 receptors on NE terminals. These SRIF receptors trigger activation of NMDA receptors through the phospholipase C (PLC)-inositol trisphosphate (IP 3 )-protein kinase C (PKC) pathway (Pittaluga et al., 2005) . 172 RAITERI tration of the drug significantly improved attention as well as working memory. A second phase II clinical trial in 280 patients with Alzheimer's disease is underway (Froestl et al., 2004) .
3. GABA B Heteroreceptors Regulating Glutamate Release. In a comparative study on the release of endogenous glutamate and endogenous GABA from human neocortex synaptosomes, the effects of three selective GABA B receptor antagonists on the inhibition of the depolarization-evoked release of the two amino acids elicited by (Ϫ)-baclofen were investigated (Bonanno et al., 1997) . Phaclofen antagonized the effect of (Ϫ)-baclofen on GABA release but did not modify that on the release of glutamate. The inhibition by (Ϫ)-baclofen of the release of GABA was insensitive to CGP35348 which, in contrast, blocked the heteroreceptors sited on glutamatergic terminals. Finally, CGP52432, added at 1 M, blocked GABA B autoreceptors, but was ineffective at the heteroreceptors. The results (Table 2) show that the release of GABA and glutamate evoked by depolarization of human neocortex nerve terminals can be affected differentially through pharmacologically distinct GABA B receptors. These human receptors seem to be very similar to those present in the rat neocortex (Bonanno and , suggesting that the rat receptors may be useful models in the development of selective ligands.
4. The Mystery of GABA B Receptor Subtypes. Receptor heterogeneity is a general phenomenon. Types and subtypes of receptors have often been identified pharmacologically on the basis of their differential blockade by antagonists. Looking at the data reported in Table 2 , the existence of subtypes of the GABA B receptor seems therefore undeniable, with strong similarities between human and rat receptors.
The problem is that, as a rule, pharmacological heterogeneity has been found to reflect structural diversity. This seems not to be the case for GABA B receptors, however. The structure of GABA B receptors is rather peculiar, the receptors being heterodimers composed of two subunits, GABA B1 and GABA B2 ; heterodimer formation is obligate for functional expression of GABA B receptors [see Bowery et al. (2002) for a review]. The mystery lies in the so far unsuccessful attempts to identify other subunits and the increasing belief that GABA B1 and GABA B2 exclusively form all GABA B receptors and that there are no further subunits to be discovered. According to some authors [see, for instance, the review by Couve et al. (2004) ], the long-standing controversy on the existence of multiple GABA B receptor subtypes in the CNS may be explained by assuming the existence and the different composition of "GABA B receptor complexes" and signaling machinery in different neurons. In other words, GABA B1 and GABA B2 subunits would associate with several proteins, giving rise to complexes (see Couve et al., 2004) that differ between neurons and may underlie the pharmacological diversity of the same heterodimer. Although the mystery remains unsolved, the differential blockade by GABA B antagonists of receptors (or receptor complexes), sited on different neurons and performing different functions, represents a pharmacological heterogeneity that can be exploited to obtain therapeutically useful GABA B receptor ligands.
VII. Glutamatergic Receptors
Excitatory amino acids have been the object of an impressive number of studies; however, functional glutamatergic transmission in human brain has been poorly investigated. Electrophysiological studies on glutamate receptors in human brain slices are described in section XII.A.1. in relation to epilepsy. Reports showing that activation of NMDA and non-NMDA ionotropic glutamate receptors can evoke release of NE from human neocortical slices (Fink et al., 1992a) , that the NE release evoked by NMDA or kainic acid can be inhibited by ethanol (Fink et al., 1992b) , and that high D-glucose, at concentrations compatible with hyperosmolar diabetic coma, differentially modifies the NMDA-evoked release of GABA and NE (Fink et al., 1994) were considered in my previous review (Raiteri, 1994) . It should be noted that glutamate ionotropic and metabotropic receptors exist as subtypes having discrete pharmacological profiles, which makes interspecies differences quite likely; more intense investigation of functional glutamatergic transmission in human brain is therefore required.
A. Metabotropic Glutamate Receptors
1. Phosphatidylinositol Turnover. Glutamate metabotropic receptors linked to phosphatidylinositol hydrolysis have been identified in human cerebellum (Nicoletti et al., 1989) and neocortex (Morari et al., 1991; Dubeau et al., 1992 ). An interesting receptor-receptor interaction seems to occur in human cerebral cortical slices where the activation of the phosphatidylinositol turnover by quisqualate was found to be prevented by NMDA, suggesting that glutamate metabotropic receptor functions in the human neocortex are negatively modulated by NMDA receptor activation (Morari et al., 1991) . Morari et al. (1995) subsequently reported on the occurrence of another receptor-receptor interaction in the human brain. The authors observed that the stimulation of the phosphatidylinositol turnover brought about by glutamate metabotropic receptor agonists could be regulated through activation of ionotropic AMPA receptors. In particular, a submaximal AMPA and metabotropic receptor activation resulted in positive cooperation. Clearly, these early works were based on determinations of phosphatidylinositol hydrolysis in the presence of non-subtype-selective metabotropic receptor agonists and would therefore deserve further consideration taking advantage of the selective ligands now available.
FUNCTIONAL PHARMACOLOGY IN HUMAN BRAIN
2. Release of Acetylcholine. In a recent work (Feligioni et al., 2003) carried out with nerve terminals prepared from human neocortex, it was found that activation of metabotropic glutamate receptors of group I elicited release of ACh through the production of inositol trisphosphate in cholinergic nerve endings. In contrast, exposure of rat cholinergic nerve endings to a metabotropic group I agonist failed to evoke ACh release. Interestingly, the HIV-1 protein Tat provoked ACh release both from human and rat synaptosomes; however, whereas in human neocortex nerve terminals Tat activates inositol trisphosphate-linked metabotropic group I receptors to elicit ACh release, the viral protein acts in rats at an as yet unidentified receptor that mediates ACh release through internal Ca 2ϩ mobilization triggered by cyclic adenosine diphosphoribose (Feligioni et al., 2003 ) (see section XIV.B. for more details).
B. N-Methyl-D-aspartate Glutamate Receptors
1. Release of Norepinephrine. The stimulation of NE release by NMDA/glycine observed in human neocortical slices by Fink et al. (1992a) could also be seen in synaptosomes isolated from human neocortical tissue (Pittaluga et al., 1996) indicating the existence of presynaptic release-enhancing NMDA receptors on human noradrenergic axon terminals. In the absence of glycine, the HIV-1 coat protein gp120 allowed NMDA to enhance the release of NE from human noradrenergic nerve endings (Pittaluga et al., 1996 ) (see section XIV.A.). Experiments with NMDA receptor antagonists led to the conclusion that gp120 mimics glycine at the receptor coagonist site on the NR1 subunit, being ϳ4 orders of magnitude more potent than the natural coagonist glycine. Of interest, gp120, which also acts at the NMDA receptors present on rat noradrenergic terminals (Pittaluga and Raiteri, 1994) , is unable to mimic glycine at the NMDA receptors sited on rat striatal dopaminergic terminals (Pittaluga et al., 2001b) . The gp120 potentiation of the NMDAevoked NE release in human brain was blocked by memantine (Pittaluga et al., 1996) , a low-affinity, uncompetitive, open-channel blocker of the NMDA receptor (Lipton and Chen, 2004) and this finding might have therapeutic implication (see section XVI.A.).
2. The "Kynurenate Test." A biochemical assay for putative cognition enhancers, termed the "kynurenate test," was introduced by Pittaluga et al. (1997) . In this test, the NMDA-evoked release of NE in rat hippocampal slices is antagonized by kynurenic acid and putative cognition enhancers are tested for their ability to counteract the kynurenate antagonism. Several behaviorally active compounds were evaluated; based on the results, the kynurenate test seems to represent a useful assay for putative cognition enhancers acting through the glutamate system via NMDA receptors (Pittaluga et al., 1997) .
It was important to establish whether compounds displaying activity in the rat brain responded similarly in a kynurenate test performed with human brain tissue. Slices from human neocortex were exposed to NMDA; the evoked release of NE was antagonized by kynurenic acid. This antagonism was potently prevented by behaviorally active compounds (aniracetam, oxiracetam, Dcycloserine, and the glutamate analog CR2249, but not its enantiomer CR2361) previously reported to positively respond in the kynurenate test performed with rat hippocampal slices (Pittaluga et al., 1999) . The similarities between the data obtained with human neocortex slices and those obtained in the rat suggest that the kynurenate test performed with rat brain slices represents a useful assay to study cognition-enhancing drugs.
VIII. Neuropeptide Receptors
Neuropeptides are important modulators of neurotransmitter function, many of them being costored and coreleased with classic transmitters (Hökfelt et al., 2000) . Although a number of studies have been performed in which release of neuropeptides from human brain tissue, particularly somatostatin and cholecystokinin, was characterized (see section VI.A.2.), very few reports deal with neuropeptide receptors in human CNS. Results from experiments with laboratory animals show that opioids can regulate neurotransmitter release, although with important species differences [see Feuerstein et al. (1996b) and references therein]. It is therefore important to investigate the modulation of release by opioids in human brain and, in particular, to characterize the subtypes of opioid receptor involved. Feuerstein et al. (1996b) enkephalin and by the -opioid receptor agonist U50488. These effects were prevented, respectively, by the ␦-opioid antagonist naltrindole and the -opioid antagonist norbinaltorphimine. Exposure to the -opioid receptor agonist D-Ala 2 -NMePhe 4 -Gly-ol 5 -enkephalin also produced ACh release inhibition; however, this effect 1) was blocked by ␦-and -opioid antagonists and 1) could not be seen with the -opioid agonists morphine and (ϩ)-nortilidine. Interestingly, naltrindole augmented, on its own, the evoked release of ACh, suggesting activation of ␦-opioid receptors by endogenous opioid peptides. Feuerstein et al. (1996b) also suggested a localization of ␦-and -opioid receptors, based on experiments in which the release of ACh was elicited by high-K ϩ in the presence of tetrodotoxin. Because the K ϩ -evoked ACh release was inhibited by U50488, but not by DPDPE, the authors proposed that -opioid receptors are presynaptic on cholinergic terminals, whereas ␦-receptors are on cortical 174 RAITERI interneurons. The nature of these interneurons remains to be established, however, because the lack of effect of GABA A and GABA B receptor agonists on ACh release tends to exclude the involvement of GABA interneurons.
A. Release of Acetylcholine Mediated by Opioid Receptors
In a subsequent work, Feuerstein et al. (1998) attempted to identify the transmitter of the interneuron acting through heteroreceptors on cholinergic terminals of the human neocortex. The authors found that the inhibition of the K ϩ -evoked ACh release by DPDPE disappeared in the presence of octreotide, a somatostatin 2 receptor agonist, suggesting that a somatostatinergic interneuron is responsible for the indirect effects of ␦-opioid receptor activation. The latter receptor was subclassified as the ␦ 1 subtype, based on the finding that the ␦ 1 -opioid receptor antagonist 7-benzylidennaltrexon prevented the DPDPE inhibition of ACh release. The authors concluded that somatodendritic ␦ 1 -opioid receptors sited on somatostatin-containing interneurons mediate inhibition of somatostatin release onto cholinergic terminals provided with facilitatory somatostatin 2 receptors, resulting in ␦ 1 receptor-mediated (indirect) depression of ACh release.
The article made no mention of the neuronal distribution of somatostatin which is largely colocalized with GABA in interneurons (Hendry et al., 1984; Somogyi et al., 1984) . Because a previous report (Feuerstein et al., 1996b) excludes the involvement of GABA receptors in the ␦-opioid inhibition of ACh release, the findings raise the possibility that ␦ 1 receptor activation selectively affects the release of the cotransmitter somatostatin, although the existence of some "pure" somatostatinergic neurons should not be excluded.
B. Release of Norepinephrine Mediated by Opioid Receptor-Like 1 Receptors
Nociceptin/orphanin FQ (N/OFQ) is a neuropeptide identified as an endogenous ligand for the opioid receptor-like 1 (ORL1) receptor (Calò et al., 2000; Mogil and Pasternak, 2001 ). The peptide was reported to inhibit the release of NE from slices of various brain areas of mouse, rat, and guinea pig (Schlicker et al., 1998; Trendelenburg et al., 2000) .
The effects of N/OFQ on the release of NE were comparatively studied in electrically stimulated slices of human and rat neocortex (Rominger et al., 2002) . N/OFQ decreased the evoked release of [ 3 H]NE in both species; the effects of N/OFQ were prevented by the ORL1 antagonist J-113397 which, on its own, was unable to increase the evoked release of [ 3 H]NE suggesting the absence of a tonic activation by endogenous N/OFQ. Although the efficacy of N/OFQ was significantly lower in human than in rat slices, the affinities of the peptide for ORL1 receptors and the pA 2 values of the ORL1 antagonist seem to be very similar in the two species.
IX. Cannabinoids and Cannabinoid Receptors
The CNS effects of ⌬ 9 -tetrahydrocannabinol, the main active constituent of marijuana and hashish and related compounds are mediated by cannabinoid receptors of the CB 1 type. These are G i protein-coupled receptors, the activation of which leads to inhibition of adenylyl cyclase. CB 1 receptors exist on presynaptic axon terminals and their activation was shown in animal studies to cause inhibition of the release of neurotransmitters, possibly consequent to inhibition of VSCCs [see Schlicker and Kathmann (2001) for a review]. Cannabinoids have been reported to modulate neurotransmitter release from fresh human brain tissue, as summarized below.
A. Release of Norepinephrine
The effects of synthetic cannabinoid receptor ligands on the release of [ 3 H]NE were comparatively analyzed in slices of human, guinea pig, rat, and mouse hippocampal tissue (Schlicker et al., 1997) . The cannabinoid receptor agonist WIN55,212-2 inhibited NE release in human and guinea pig hippocampal slices, but not in slices of rat and mouse hippocampus. The CB 1 receptor antagonist SR141716 markedly attenuated the WIN55,212-2-induced inhibition of NE release, suggesting that activation of CB 1 receptors mediate inhibition of NE release in human and guinea pig hippocampus. The modest augmentation of NE release provoked by SR141716, when added alone to human slices, suggests that CB 1 receptors may not be tonically activated in the human cerebrocortex.
The hippocampal formation is one of the brain regions with the highest level of CB 1 receptor expression (Herkenham et al., 1990) . Cannabinoids are known to interfere with hippocampal functions; in particular, they cause impairments in memory consolidation and association in humans (Ameri, 1999; Hampson and Deadwyler, 1999) . Noradrenergic transmission is positively involved in cognitive processes (Berridge and Waterhouse, 2003) . Therefore, the observed inhibitory effect of CB 1 receptor activation on the release of NE in the hippocampus may be of some relevance to the cognitive impairments induced by cannabinoids.
B. Release of GABA
Starting from the reported existence of cannabinoid CB 1 receptors on the axon terminals of GABA interneurons of the rodent hippocampus (Tsou et al., 1999) and the inhibitory action of CB 1 receptor activation on the release of GABA (Katona et al., 1999) , it was important to ascertain the existence of CB 1 receptors on GABAergic neurons in human hippocampus and to investigate cannabinoid effects on GABA release.
Using control postmortem and epileptic lobectomy tissue, Katona et al. (2000) found CB 1 receptors to be expressed on GABA interneurons and concentrated in axon terminals. In functional experiments with human Thus, the localization on GABAergic axon terminals of hippocampal interneurons and the inhibitory function on GABA release of CB 1 receptors seem to be evolutionarily conserved, which makes the rat hippocampus an appropriate model of native CB 1 receptors useful to develop new CB 1 selective ligands. According the Katona et al (2000) , the actions of exogenous cannabinoids and of endocannabinoids on GABAergic interneuronal networks may underlie some of their hippocampus-related behavioral effects. Steffens et al. (2003) compared the effects of cannabinoids on the release of ACh in human and mouse neocortex. Brain slices were labeled with [
C. Release of Acetylcholine
3 H]choline and stimulated electrically in superfusion conditions. The addition of WIN55,212-2 decreased ACh release; the CB 1 antagonist SR141716 prevented the inhibitory effect of WIN55,212-2, indicating that activation of CB 1 receptors may diminish ACh release in human neocortex.
The results of Steffens et al. (2003) also suggest that these CB 1 receptors are tonically activated by endocannabinoids released by depolarizing stimuli and which seem to accumulate in the biophase of CB 1 receptors depending on the stimulation conditions. The assumption of an endocannabinoid tone on CB 1 receptors modulating ACh release in human (but not in mouse) neocortex is justified by at least two observations: 1) SR141716 enhanced, on its own, the release of ACh in human (but not the mouse) neocortical slices and 2) the endocannabinoid uptake blocker AM404 inhibited the release of ACh in human (but not in mouse) brain tissue, probably due to increased endocannabinoid levels in the CB 1 receptor biophase.
Cannabinoids are known to impair cognition and memory, probably due to interference with various transmitter systems. Among these, the cholinergic transmission may play a role [see Sullivan (2000) for a review]. According to Steffens et al. (2003) , the facilitatory effect of SR141716 on the release of ACh in the human neocortex suggests that cannabinoid CB 1 receptor antagonists may be useful in the treatment of dementia. Steffens et al. (2004) (Hermann et al., 2002) , indicating that the rodent brain may not represent a suitable model to investigate cannabinoid-dopamine interactions in the neocortex.
D. Release of Dopamine
When the CB 1 receptor antagonist AM251 was added alone to the human slices, a concentration-dependent increase in DA release was observed. Again AM251 was ineffective on DA release in the rat. One likely explanation for the AM251 effect is the disruption of an endocannabinoid tone that keeps the release of DA in human neocortex partly depressed (Steffens et al., 2004) .
The addition of CP55940 to human neocortex synaptosomes reduced the forskolin-stimulated cyclic AMP accumulation, an effect mediated by CB 1 receptors because it was antagonized by AM251. Steffens et al (2004) speculated that CB 1 receptor activation may depress DA release not only by impairing the function of VSCCs but also by inhibiting adenylyl cyclase. Whether VSCCs and adenylyl cyclase are functionally connected in nerve terminals remains to be established.
To conclude, the work by Steffens et al. (2004) provides evidence for the presence of G i protein-coupled CB 1 receptors modulating DA transmission in the human neocortex. These receptors seem not to exist in the rat neocortex. Moreover, the CB 1 receptors in human neocortex are tonically activated by endogenous cannabinoids or/and exhibit constitutive activity. If CB 1 receptor antagonists elicit DA release in the human neocortex, they may be used for the treatment of cognitive deficits associated with a decreased cortical dopaminergic transmission (Brever and Barch, 2002) .
X. Calcium Channels and Intraterminal Calcium Pools
A. Voltage-Sensitive Calcium Channels
Influx of Calcium and Norepinephrine
Release. Human cerebral cortical synaptosomes were used by Meder et al. (1999) to study VSCCs. Fura-2-loaded synaptosomes were depolarized by exposure to high-K ϩ or to veratridine. Both agents increased intraterminal [Ca 2ϩ ], but the influx of external Ca 2ϩ into nerve terminals involved distinct VSCCs. In particular, the increase of intraterminal [Ca 2ϩ ] caused by K ϩ depolarization predominantly occurred by activation of P/Q-type Ca 2ϩ channels and, less so, by N-type channels, whereas that caused by veratridine involved activation of P/Q-, N-and L-type Ca 2ϩ channels. Moreover, a small portion of the veratridine-evoked increase of intraterminal [Ca 2ϩ ] was 176 RAITERI resistant to VSCC blockade and might represent intraterminal Ca 2ϩ accumulation via the Na ϩ /Ca 2ϩ exchanger. Based on previous data with rat synaptosomes (Meder et al., 1997) , the authors pointed out that there are considerable differences in presynaptic VSCCs between human and rat brain cortex. Fink et al. (2002) subsequently tested the effect of gabapentin and pregabalin, two drugs efficacious in the treatment of epilepsy and neuropathic pain, on the K ϩ -induced intraterminal [Ca 2ϩ ] increase in fura-2-loaded human neocortical synaptosomes. Both drugs inhibited the K ϩ -induced increase of intraterminal [Ca 2ϩ ]; the effect of gabapentin was prevented by the P/Q-type VSCC blocker -agatoxin IVA, indicating interaction with presynaptic VSCCs of the P/Q-type. As previously observed in rats, both gabapentin and pregabalin seem to bind to the ␣2␦ subunit of VSCCs (Bryans and Wustrow, 1999) ; Fink et al. (2002) found ␣2␦-1, ␣2␦-2, and ␣2␦-3 subunits to be present in human neocortical synaptosomes by immunoblot analysis. In neurotransmitter release experiments with human neocortical slices, gabapentin inhibited the K ϩ -evoked release of [ 3 H]NE, an effect that was prevented by blocking glutamate receptors of the AMPA type. The authors proposed that gabapentin and pregabalin may bind to the ␣2␦ subunit of P/Q-type VSCCs to inhibit Ca 2ϩ influx into and glutamate release from excitatory amino acid terminals that impinge on noradrenergic nerve endings, as previously shown to occur in rat neocortical slices (Doodley et al., 2000; Fink et al., 2000) . The reduced cytosolic [Ca 2ϩ ] and decreased glutamate release caused by gabapentin and pregabalin may effectively attenuate neuronal excitability to explain the clinical efficacy of these drugs.
Influx of Calcium and Nitric-Oxide
Synthase Activity. Nitric-oxide synthase activity was studied in slices of human temporal cortex samples by measuring the conversion of tritiated L-arginine to L-citrulline (Fontana et al., 1997) . Elevation of extracellular [K ϩ ], an event that can occur in a number of pathological conditions such as cerebral ischemia (Zetterström et al., 1995) and epilepsy (Louvel et al., 1994 (Louvel et al., , 2001 , augmented Lcitrulline production. The response to high-K ϩ was abolished by inhibiting NO synthase or blocking VSCCs with 10 mM Mg 2ϩ . Glutamate receptors seem not to be involved because the K ϩ effect was insensitive to selective antagonists. The K ϩ (35 mM)-evoked activation of NO synthase was insensitive to -conotoxin GVIA and to nifedipine, but could be prevented in part by -agatoxin IVA. Interestingly, the inhibition caused by -agatoxin IVA was enhanced by adding -conotoxin GVIA or nifedipine. Further inhibition could be observed when the three VSCC blockers were added together. Fontana et al. (1997) concluded that elevation of extracellular [K ϩ ] causes NO synthase activation by external Ca 2ϩ entering cells mainly through channels of the P/Q-type. Other VSCCs (L-and N-type) seem to contribute when P/Qtype channels are blocked (functional compensation?).
Assuming that the present scenario reflects what occurs in some of the physiopathological conditions in which NO has been implicated, association of Ca 2ϩ channel blockers or nonselective blockers may deserve better consideration than selective P/Q-type channel blockers as potential therapeutic agents.
B. Calcium Pools and Dopamine Release
Bonanno et al. (2000) used human neocortex synaptosomes to study the release of DA provoked by various stimuli. Exposure in superfusion to 15 mM KCl, 100 M 4-aminopyridine, 1 M ionomycin or 30 mM caffeine elicited almost identical DA overflows. Removal of external Ca 2ϩ abolished the overflows evoked by high-K ϩ or ionomycin and largely prevented that caused by 4-aminopyridine, whereas the release evoked by caffeine remained unaffected. The Ca 2ϩ chelator BAPTA reduced significantly the K ϩ -and the caffeine-evoked DA overflows. The effect of caffeine was attenuated by the ryanodine receptor blocker dantrolene or by the inositol trisphosphate receptor antagonist heparin and abolished by the combined addition of dantrolene and heparin. Tetanus toxin inhibited the K ϩ -or the 4-aminopyridine-evoked release of DA; in contrast, the releases stimulated by ionomycin and by caffeine were totally insensitive to the toxin. To conclude, DA release from human neocortex nerve terminals can be triggered by Ca 2ϩ ions originating from various sources. It seems that stimuli not leading to activation of VSCCs elicit Ca 2ϩ -dependent, probably exocytotic, release that, under the experimental conditions used, seems insensitive to tetanus toxin. A caffeine-stimulated DA release has rarely been observed in animal brain preparations. In fact, caffeine increased rat striatal DA release during in vivo microdialysis, but the effect was indirectly mediated through the known blocking activity of caffeine at adenosine receptors (Okada et al., 1997) . The characteristics of the superfusion technique used to monitor DA release and the results with ryanodine and inositol trisphosphate receptor blockers permit to conclude that caffeine acts directly on human nerve terminals and causes release of DA by mobilizing Ca 2ϩ ions from the endoplasmic reticulum of mesocortical dopaminergic neurons. The release of DA in the neocortex might be involved in the stimulatory and cognition enhancing properties of caffeine.
XI. Neurotransmitters in the Alzheimer's Brain
Alzheimer's disease is a progressive neurodegenerative disorder characterized by various mental dysfunctions including cognitive impairments, reduction in intellectual abilities, emotional instability and changes in personality. The most well-appreciated neuronal loss is in the cholinergic system (Coyle et al., 1983; Perry, 1986; Fibiger, 1991; Nordberg, 1999) . However, other neuronal systems are affected, including noradrenergic, sero-FUNCTIONAL PHARMACOLOGY IN HUMAN BRAIN tonergic, GABAergic, and peptidergic neurons (Palmer, 1996) .
In general, reliable release and uptake results can only be obtained by using fresh brain tissue preparations. The availability of fresh Alzheimer's tissue was an extremely rare event dating back to the 1980s, when small amounts of brain tissue were removed to provide a definitive diagnosis or to apply a therapeutic agent (Neary et al., 1986) . Studies of functional neurochemistry with these bioptic specimens provided the greatest contribution to understanding of the pathogenesis of Alzheimer's disease (see below).
The vast majority of the studies on the Alzheimer's brain have been performed using postmortem tissues. Although meaningful data can be obtained from diseased postmortem human brain, interpretation of postmortem results requires careful consideration of potentially confounding factors including agonal state, possible tissue atrophy, energy failures due to postmortem delay, and so forth (see, for a detailed discussion, Palmer, 1996) .
Because of the difficulties in performing functional experiments with postmortem tissues, studies on neurotransmitter receptors and transporters have been carried out with radioligand binding techniques. This approach may have some yet poorly considered drawbacks. It is now amply accepted that receptors and transporters travel from internal stores to the plasma membrane and vice versa; moreover, the proteins actively present on the plasma membrane may only represent a minority, the large majority being stored intracellularly. Thus, the possibility exists that classic radioligand techniques cannot easily discriminate between the two protein pools, leading to erroneous interpretations.
A. Functional Studies of Alzheimer's Brain Antemortem
Experiments with biopsy tissues have been important in the study of Alzheimer's disease for a number of reasons. The data obtained helped to separate changes related to the disease from the artefacts and epiphenomena associated with postmortem conditions. The results allowed identification of changes occurring early in the disease process. Moreover, antemortem tissue has offered the opportunity to relate neurochemistry to certain behavioral changes characteristic of Alzheimer's disease. Antemortem brain tissue suitable for functional studies will obviously not be available from patients with Alzheimer's disease. As recently reviewed by Cattabeni et al. (2004) , platelets seem to provide human tissue useful to unravel the pathogenic mechanisms of Alzheimer's disease.
1. The Cholinergic System. Reduced activity of choline acetyltransferase in Alzheimer's disease was an early observation (Bowen, 1977) . In a comparison of the enzyme activity in tissue of control subjects removed antemortem and postmortem, choline acetyltransferase seemed to be very stable postmortem (Palmer et al., 1988) . Using crude synaptosomal preparations from Alzheimer's disease neocortex it was found that ACh synthesis and choline uptake were reduced with respect to controls (Sims et al., 1983; Palmer et al., 1987c) . The antemortem biopsies used were obtained ϳ3.5 years after the onset of symptoms, which is approximately at the midpoint of the disease. These results indicate that neocortical cholinergic projections are lost at an early stage of the disease.
2. The Monoaminergic Systems. Histological data indicate loss of serotonergic perikarya in the dorsal raphe nucleus of the Alzheimer's brain (Mann et al., 1984) . Antemortem studies show that the release and uptake of 5-HT in the Alzheimer's temporal cortex are both reduced with respect to controls (Palmer et al., 1987a,c) . The damage to serotonergic neurons seems to occur early in the course of the disease since the loss of serotonergic markers was evident in a subset of patients that had displayed clinical symptoms for Ͻ2 years (Palmer et al., 1987a) .
Studies of Alzheimer's tissue removed antemortem show that the concentration of NE was reduced both in temporal and frontal cortex. In addition, high-affinity uptake of the [ 3 H]catecholamine was lower in the pathological than in control tissue. Moreover, these changes were evident in a subset of patients who had displayed clinical symptoms for Ͻ2 years, suggesting that dysfunction of the noradrenergic system also occurs early in the course of the disease (Palmer et al., 1987b) .
In a study of antemortem cortical tissue from subjects with Alzheimer's disease, the concentrations of DA and its metabolites were all unaffected, suggesting that DA nerve terminals in the neocortex are spared in Alzheimer's disease (Palmer et al., 1987b,c) . In contrast to the cerebral cortex, reduced concentrations of homovanillic acid were observed in postmortem neostriatal tissue of patients with a clinical diagnosis of Alzheimer's disease (Palmer et al., 1984) , suggesting a dysfunction in striatal DA transmission. Accordingly, parkinsonian symptoms commonly accompany Alzheimer's disease (Tyrrell et al., 1990; Joyce et al., 1998; Werber and Rabey, 2001) . In a recent report (Zhang et al., 2004) , it was observed that the use of cholinergic drugs for Alzheimer's disease, in particular the acetylcholinesterase inhibitors donepezil and galantamine, can enhance DA release by indirectly acting at, or allosterically modulating (Svensson and Nordberg, 1996) , nicotinic AChRs present on DA terminals, which may underlie the influence of these drugs over some noncognitive symptoms of Alzheimer's disease, including motor dysfunctions.
3. Somatostatin. Some neuropeptides seem to be positively involved in cognitive processes. Among these, somatostatin, a neuropeptide particularly concentrated in the cerebral cortex and the hippocampus (Rubinow et al., 1995; Barton, 2003) , has attracted considerable interest. Reduction of somatostatin levels in the cortical 178 RAITERI areas is an autoptic finding typical of Alzheimer's disease (Davies et al., 1980; Beal et al., 1986; Dawbarn et al., 1986; Chan-Palay, 1987; Gabriel et al., 1993) . Although the only study on somatostatin release with antemortem Alzheimer's temporal cortex tissue (Francis et al., 1987) showed only a nonsignificant decrease, the abundant results reporting significant reductions in the neuropeptide concentration also in the cerebrospinal fluid of patients (Minthon et al., 1997) suggest that, at least in the advanced stages of Alzheimer's disease, the somatostatinergic transmission is severely impaired (Palmer, 1996) .
XII. Epilepsy: In Vitro and in Vivo Studies
A. The GABA and Glutamate Systems in Epilepsy
Temporal lobe epilepsy (TLE) is the most frequent and severe form of adult focal epilepsy. In many patients TLE is refractory to anticonvulsant drug therapy. A relevant proportion of these patients are treated by surgical removal of the epileptic focus, which usually comprises a portion of the temporal lobe including the hippocampus. Although the difficulty in obtaining control human tissue is obviously of major concern, studies using resected human focal epileptic tissues provide a unique opportunity to compare results derived from animal models of TLE with the human condition. Most of the studies described below have produced results that show clear similarities between the epileptic human and epileptic rat models, indicating that animal investigation can be of help in understanding the pathological aspects of the disease and in the development of novel mechanism-based, therapeutic modalities.
1. GABA and Glutamate Receptors: Electrophysiological Studies. Avoli et al. (1991) examined the epileptiform activity induced by low extracellular Mg 2ϩ in slices of human epileptogenic neocortex obtained during neurosurgical procedures. Spontaneous epileptiform activity and episodes of spreading depression appeared within 1 to 2 hours of perfusion with Mg 2ϩ -free artificial cerebrospinal fluid. Transient increases in extracellular [K ϩ ] were associated with each epileptiform discharge. Spreading depression episodes were accompanied by increases in external [K ϩ ] of up to 100 mM. Epileptiform discharges and spreading depressions were abolished when glutamate NMDA receptor antagonists were present, whereas blockade of ionotropic non-NMDA receptors did not influence the epileptiform activity elicited by lack of Mg 2ϩ ions . It was also shown that blockade of the GABA A receptors is sufficient to elicit epileptiform discharges in the human neocortex in vitro (Hwa et al., 1991) .
Studies in the hippocampus and neocortex of rodents had reported that synchronous potentials could be recorded upon application of the K ϩ channel blocker 4-aminopyridine (4-AP), even after excitatory amino acid receptors had been blocked by specific antagonists.
Curiously, these phenomena seem to be mediated by the activities of GABA A receptors (Michelson and Wong, 1991; Perrault and Avoli, 1992) . Similar to what was observed in normal rats, application of 4-AP to slices of human neocortex obtained in the course of neurosurgery for the relief of intractable seizures disclosed synchronous field potentials that correlate with a long-lasting depolarization and are mainly due to GABA A receptor activation. Of note, activation of glutamate receptors is not required for the generation and propagation of these GABA-mediated potentials . The authors proposed that these potentials represent a novel mechanism for synchronization and spread of neuronal activity, including seizure-like discharges in the human neocortex.
In line with the results obtained by Avoli et al. (1994) with 4-AP, Williamson et al. (1995) reported that, in some situations, GABA could act as an excitatory neurotransmitter. These authors studied the responses to exogenously added GABA of dentate granule cells in slices isolated from patients with temporal lobe sclerosis. The cells examined exhibited reduced synaptic inhibition with concomitant hyperexcitability relative to the dentate granule cells in the hippocampi of patients with temporal lobe tumors in which cell sclerosis was not detectable and which were taken as "controls." To understand the reason for the disinhibition, Williamson et al. (1995) monitored the responses to exogenously applied GABA. The responses studied at the resting membrane potential were depolarizing and were mediated by GABA A receptors. In many cases, these depolarizing GABA responses could trigger action potentials. Interestingly, the GABA A receptor-mediated responses in the sclerotic hippocampi were ϳ80% longer than those in the comparison population. As one explanation, the authors suggest that the GABA transport system could be impaired in the sclerotic tissue (see below).
The glutamate-independent, GABA A receptor-mediated, synchronous activity that occurs in human neocortex slices exposed to 4-AP was further characterized by field potential and extracellular [K ϩ ] recordings (Louvel et al., 2001 ). These synchronous potentials are associated with elevations in extracellular [K ϩ ] that may contribute to their origin and spread within the neocortex. The synchronous potentials, previously found to be blocked by GABA A receptor antagonists, disappear following activation of -opioid receptors expected to block GABA release (Capogna et al., 1993) , are significantly reduced by activation of GABA B receptors of undefined (probably presynaptic) localization, and seem to be modulated by metabotropic glutamate receptors of group I (Louvel et al., 2001) .
Using patch-clamp recording techniques in dentate granule cells isolated from tissue resected from patients undergoing temporal lobectomy, Shumate et al. (1998) compared properties of human GABA A receptors to GABA A receptor properties in control and epileptic rats.
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Of note, both the epileptic human and epileptic rat models exhibited the same pattern of neuropathology, in particular mesial temporal sclerosis and mossy fiber sprouting (Coulter et al., 1996) . Both epileptic human and epileptic rat dentate granule cells exhibited GABA A receptor responses, which were strongly blocked by zinc, in contrast to the weak zinc sensitivity observed in control rat dentate granule cells. Zinc ions are released by the sprouted mossy fibers autoinnervating the dentate granule cells in the epileptic hippocampus. According to the authors, the enhanced zinc sensitivity exhibited by GABA A receptors may underlie an important failure of inhibition in the epileptic dentate gyrus where zinc is released from the mossy fiber terminals. Shumate et al. (1998) hypothesized that the enhanced zinc sensitivity may result from underlying shifts in subunit composition of GABA A receptors in the epileptic dentate gyrus. Considering the similarities between responses in human and rat isolated granule cells, useful information on the GABA A receptor subtypes involved could be obtained from animal models.
Intracranial electroencephalogram records from hippocampal structures in patients with TLE usually reveal interictal spikes, which occur between seizures. To study the origin and the mechanisms of this phenomenon, specimens resected from 21 patients that included the hippocampal formation were examined electrophysiologically (Cohen et al., 2002) . The authors always detected rhythmic and synchronous extracellular spikes in records from the subiculum, an output hippocampal area that projects to the temporal cortex and is innervated by CA1 pyramidal cell axons. These synchronous events were similar to interictal discharges of patient electroencephalograms. Interestingly, synchronous discharges were suppressed by AMPA or NMDA glutamate receptor antagonists, as well as by GABA A receptor antagonists. Recording from different subicular sites indicates that the network of discharging neurons comprises both subicular interneurons and a subgroup of pyramidal cells. In these pyramidal cells, GABAergic signaling is depolarizing since GABAergic synaptic events reversed at depolarized potentials. The authors concluded that depolarizing GABAergic responses in neurons downstream to the sclerotic CA1 region contribute to human interictal activity. One possibility raised to explain the GABA A receptor-evoked depolarization is that the altered connectivity associated with damaged temporal lobe, including neuronal deafferentation, may lead to a switch of the neuron to an immature state in which GABA A -mediated responses are known to be depolarizing (Cherubini et al., 1991) .
It has to be noted that GABA A receptor-mediated depolarizing responses are not limited to immature CNS neurons or to pathological conditions such as epilepsy; indeed, there are numerous reports showing that GABA can exhibit "physiological" depolarizing actions in mature CNS neurons (Staley et al., 1995; Fassio et al., 1999; Gulledge and Stuart, 2003) [see Stein and Nicoll (2004) for a recent review].
Hippocampal specimens resected to cure intractable TLE can be useful to investigate the functional consequences of morphological alterations. In cases of hippocampal sclerosis, morphological investigation shows an atypical network of granule cells synaptically interconnected through aberrant supragranular mossy fibers. In a very recent work, Gabriel et al. (2004) investigated whether granule cell populations in slices from sclerotic and nonsclerotic hippocampi would develop epileptiform activity following low-frequency hilar stimulation in the presence of elevated extracellular [K ϩ ] and whether the experimental activity differs according to the presence of aberrant mossy fibers. The authors found that ictaform activity could be provoked in slices from both sclerotic and nonsclerotic hippocampi. However, the induction of ictaform discharges in slices from sclerotic hippocampi required lower concentrations of K ϩ (i.e., lower depolarization) than in slices from nonsclerotic hippocampi, suggesting that synaptically coupled granule cells in the reorganized network, when depolarized by high-K ϩ , could cooperate to reach the threshold for seizure generation. Gabriel et al. (2004) reported that the two groups of patients also differed with respect to the pattern of epileptiform discharges. On the other hand, the different ictaform activities seemed to be synaptic in origin because they were dependent on external Ca 2ϩ and disappeared in the presence of glutamate AMPA receptor blockade. According to the authors, the fact that it is possible to induce epileptiform activity in slices from neurosurgically removed human tissue permits investigation of mechanisms of drug resistance and evaluation of the advantages of newly developed drugs over presently available anticonvulsants.
In Vivo Microdialysis in Epileptic Patients
: Glutamate/GABA Release and GABA Transporters. Glutamate is the major excitatory transmitter, and GABA is the major inhibitory transmitter in the CNS. Monitoring amino acid levels during intracerebral microdialysis in seven patients with medically intractable epilepsy, Ronne-Engstrom et al. (1992) had found dramatic increases of extracellular glutamate, aspartate, glycine, and serine in association with focal seizures. During and Spencer (1993) subsequently used bilateral intrahippocampal microdialysis to test the hypothesis that an increase in extracellular glutamate may trigger spontaneous seizures in the conscious human brain. The concentrations of glutamate and GABA were measured in the microdialysate before and during seizures in six patients with complex partial epilepsy investigated before surgery. Interestingly, a rise in glutamate was observed in the epileptogenic hippocampus just before the seizure. Because perfusion of glutamate into the cat hippocampus in vivo induces seizures (Biscoe and Straughan, 1966 ), the results with epileptic patients 180 RAITERI suggest that an increase in the extracellular endogenous glutamate may do the same. Opposite to glutamate, the concentrations of GABA in the epileptogenic hippocampus were lower than those in the nonepileptogenic side. Moreover, whereas the increase in glutamate preceded seizures, GABA concentrations were unchanged before seizures, but increased during them and remained higher in the nonepileptogenic hippocampus. The glutamate/GABA ratio is raised in the epileptogenic hippocampus, particularly in the postseizure period, when glutamate remains high as the GABA concentration returns to normal, which might contribute to the lesions characteristic of TLE.
As compounds that block the synthesis, the release, or the postsynaptic receptors of GABA can induce convulsions, epilepsy may not only originate from an excess of excitatory transmission but also from alterations of the inhibitory effects of GABA, in particular a shortfall in the amount of GABA released. To test the hypothesis that the epileptogenic region in temporal lobe epilepsy is characterized by an alteration in the release of GABA, microdialysis was performed in eight awake patients (During et al., 1995) . The local perfusion of glutamate induced an increase of GABA release which was independent of external Ca 2ϩ ions in the nonepileptogenic hippocampus but much less so in the epileptogenic hippocampus. GABA release from neurons is of two types Raiteri, 1974, 1993) : physiological release is vesicular, external Ca 2ϩ -dependent, and sensitive to clostridial toxins, and it can be evoked by depolarizing stimuli. The amino acid can also be released from neurons and glia (Gallo et al., 1991) by a Ca 2ϩ -independent carrier-mediated process, whereby GABA is released through the GABA transporter working in the insideoutside direction; such a reversal in transport can be triggered by various stimuli, including glutamate and "pathologically" elevated extracellular K ϩ concentrations (Drejer et al., 1987; Patrylo et al., 2001; Raiteri et al., 2002b) and is blocked by GABA transporter inhibitors.
In the work of During et al. (1995) , it was reported that the number of GABA transporters is reduced in the epileptogenic hippocampus, which would imply that, if release of GABA during seizures occurs by reversal of GABA transport, the amounts of GABA released could be insufficient to counteract seizure activity. The possibility that the reduction in glutamate-induced GABA release is due to loss of ionotropic glutamate receptors is unlikely because both NMDA and ionotropic non-NMDA electrophysiological responses are maintained in resected epileptogenic tissue (Isokawa et al., 1991; Williamson, 1994) . Following the oral administration of the GABA transporter blocker tiagabine in patients with mesial TLE, the extracellular GABA in the epileptogenic hippocampi was found to be diminished (During et al., 1992) . Moreover, GABA-induced responses in granule cells recorded in vitro from epileptogenic hippocampal slices are significantly prolonged (Williamson et al., 1995) . Altogether, these results support the hypothesis that GABA transporter function is abnormal in epileptogenic tissue. Accordingly, it was previously shown that the seizure-induced increase in extracellular GABA in epileptic patients is diminished in the epileptogenic hippocampus (During and Spencer, 1993) . In conclusion, During et al. (1995) proposed that, during periods of intense neuronal and glial excitation, release of GABA can occur by transporter reversal triggered by depolarizing glutamate receptor activation (Fig. 3) , which would represent a defense mechanism against excessive glutamatergic excitation. The loss of function of GABA transporters proposed by During et al. (1995) would diminish the carrier-mediated release of the inhibitory transmitter, thus contributing to the epileptogenic state in human mesial TLE.
3. The Glutamate-Glutamine Cycling in Epilepsy. If high extracellular glutamate concentrations are considered as a likely trigger of seizures in mesial TLE, the underlying mechanisms are not understood. As one possibility, Eid et al. (2004) investigated whether a deficiency in glutamine synthetase could explain the "hyperglutamatergicity" present in this pathological condition. It is well known that extracellular glutamate is largely taken up by astrocytes and converted by glutamine synthetase to glutamine. A glutamine synthetase deficiency would therefore be expected to cause increase in glutamate in the astrocytes, with consequent accumulation of extracellular excitatory amino acid (see Fig. 3 ).
As previously reported, During and Spencer (1993) had shown, in their in vivo microdialysis study, that extracellular glutamate concentrations in the epileptogenic hippocampus of patients increased just before a seizure. More recently, the glutamate-glutamine cycling was found to be slower in the hippocampus of patients with mesial TLE (Petroff et al., 2002) . Eid et al. (2004) obtained hippocampal tissue from 29 patients; the surgically resected hippocampi were classified into two groups: mesial TLE and nonmesial TLE. In Western blots, the expression of glutamine synthetase was 40% lower in mesial TLE than in nonmesial TLE samples. The enzyme activity was 38% lower in mesial TLE versus nonmesial TLE. Of note, the reduction in glutamine synthetase was particularly pronounced in areas of the mesial TLE hippocampus with astroglial proliferation, which is surprising considering the fact that normal astrocytes are especially rich in glutamine synthetase. As the glutamate uptake seems not to be impaired (Eid et al., 2004) , the deficiency in glutamine synthetase is likely to play a major role in the accumulation of extracellular glutamate observed in the epileptogenic hippocampus (During and Spencer, 1993) .
It remains to be established how the impairment of enzyme activity occurs and whether a deficiency in glutamine synthetase can indeed represent a causative factor for the chronic seizures and the hippocampal sclero-FUNCTIONAL PHARMACOLOGY IN HUMAN BRAIN sis characteristic of mesial TLE. In the positive and animal studies suggesting that this may be the case [see Eid et al. (2004) for references], regulation of glutamine synthetase activity might constitute a novel approach in the therapy of temporal lobe epilepsy.
B. Calcium Channels and Epilepsy
Dynorphin is a neuropeptide highly expressed in the dentate granule cells of the hippocampus, which acts on opiate receptors of the type (Chavkin et al., 1982) . Dynorphin can have a number of inhibitory effects including inhibition of glutamate release (Weisskopf et al., 1993) , modulation of NMDA receptors (Chen et al., 1995) , and block of VSCCs (Ingram et al., 1997) . It has been hypothesized therefore that dynorphin may act as an endogenous anticonvulsant (Snead and Simonato, 1991) . Jeub et al. (1999) investigated whether dynorphin can affect VSCC function in hippocampal granule cells isolated from two patient groups, one with a histopathological diagnosis of Ammon's horn sclerosis (AHS) and the other showing a lesion in the temporal lobe that did not involve the hippocampus proper. The patients in the AHS group showed strong dynorphin immunoreactivity in the inner molecular layer of the dentate gyrus, indicating recurrent mossy fiber sprouting. In contrast, no such dynorphin-immunoreactive structures were observed in the patients of the lesion group. In patients without mossy fiber sprouting, the application of dynorphin A caused a naloxonesensitive concentration-dependent depression of VSCCs in most granule cells. In contrast, significantly less dentate granule cells displayed inhibition of VSCCs by dynorphin A in patients with mossy fiber sprouting. Because large amounts of dynorphin are present in recurrent mossy fiber collaterals, one possible explanation is that receptors undergo down-regulation secondary to a chronic stimulation by dynorphin. Whatever the reason, a modulatory feedback pathway linking neuronal activity with dynorphinmediated inhibition of VSCCs seems not to be present in patients with AHS (Jeub et al., 1999) . With moderate increases in extracellular glutamate, Na ϩ entry through ionotropic glutamate receptors triggers carrier-mediated release of GABA through GAT-1 transporters. Excess glutamate is captured by EAAT1/2 transporters into glial cells and transformed into glutamine by glutamine synthetase (GS). Moderate increases of extracellular [K ϩ ] potentiate GABA exocytosis. b, epileptogenic hippocampus. In response to elevated glutamate concentration, as may be seen with excessive excitation before seizure generation (During and Spencer, 1993) , following glutamine synthetase deficiency (Eid et al., 2004) , and/or consequent to GABA Areceptor mediated depolarizing signals , there is insufficient GABA efflux reflecting the loss of GABA transporters (During et al., 1995) . The decreased availability of GABA transporters for carrier-mediated release becomes particularly relevant in presence of strong extracellular [K ϩ ] elevation (not shown), a condition in which the extra release of GABA may exclusively occur by transporter reversal (Cheng et al., 1994; Klapstein et al., 1998 ). Nä gerl et al. (2000 addressed the regulation by CB of Ca 2ϩ influx into human hippocampal neurons that survived AHS associated with mesial TLE, using acutely isolated dentate granule cells. It was found that, in patients with AHS, the loss of CB from granule cells markedly increased the Ca 2ϩ -dependent inactivation of VSCCs, thereby decreasing the entry of Ca 2ϩ during repetitive neuronal firing. Interestingly, when purified CB was introduced into granule cells, the inactivation of Ca 2ϩ currents was restored to levels observed in cells with normal CB content obtained from patients with TLE but without AHS. These results support the idea that the loss of CB is neuroprotective. It is known that AHS is characterized by a dramatic loss of hippocampal neurons including the hilus and the CA1, CA3, and CA4 regions, whereas dentate gyrus granule cells are more resistant to the damage . According to Näg-erl et al. (2000) , the loss of CB may contribute to the selective resistance of these cells in AHS because it limits Ca 2ϩ influx through an enhanced Ca 2ϩ -dependent inactivation of VSCCs during prolonged neuronal discharges.
XIII. Brain Ischemia and Traumatic Injury
It is widely accepted that extracellular accumulation of excitatory amino acids, in particular glutamate, is an early event in brain ischemia, involved in membrane depolarization and in excitotoxic neuronal damage [see Choi (1988) , Attwell (1994), Nieber (1999) , and references therein]. In patients with cerebral ischemia, but also with acute brain injury, a relation was indeed observed between the extracellular glutamate concentration and neurological deficits (Castillo et al., 1996; Persson et al., 1996; Bullock et al., 1998) . Although the dependence of the excitotoxic damage on ionotropic glutamate receptor activation and the neuroprotective effects of glutamate receptor blockers (Szatkowski and Attwell, 1994; Lipton, 1999; Nieber, 1999) are consistent with neuroprotection being related to inhibition of excessive glutamate transmission, including elevated glutamate release (De Cristobal et al., 2001; Castillo et al., 2003) , the question arises as to whether the control of glutamate efflux alone can be neuroprotectant in brain ischemia (Calabresi et al., 2000) .
The possibility of controlling extracellular glutamate accumulation during ischemia rests on the knowledge of the mechanisms of glutamate efflux. Reversal of glutamate transporters (Levi and Raiteri, 1993; Szatkowski and Attwell, 1994; Jabaudon et al., 2000; Rossi et al., 2000) , vesicular exocytosis (Drejer et al., 1985; Katchman and Hershkowitz, 1993; Jehle et al., 2000) and swelling-induced efflux through glial anion channels (Bednar et al., 1992) have been reported to occur in varying proportions during ischemia. Most likely, different modes of glutamate efflux become preponderant, depending on the ischemia model adopted and on the degree of oxygen/glucose deprivation reached in the tissue. Rapid and severe ischemia (such as oxygen/glucose deprivation plus inhibition of glycolysis and mitochondrial respiration) could mimic events occurring in the highly anoxic core of the ischemic area, with extreme energy failure in the mitochondria. The efflux of glutamate caused by such severe conditions applied to rat hippocampal slices was reported to take place almost entirely by carrier-mediated release (Rossi et al., 2000) . It is conceivable that moderate ischemia better reflects events occurring in the penumbral zone surrounding the ischemic core, i.e. the zone that may be targeted by therapeutic intervention. (Marcoli et al., 2004) .
Superfusion with Ca 2ϩ -free medium or with tetrodotoxin reduced by ϳ50 and 65%, respectively, the glutamate efflux, compatible with a vesicular exocytotic mode of exit of glutamate from human cerebrocortical slices exposed to ischemia. Vesicular glutamate release is usually considered to be of neuronal origin, although glial cells may well contribute to Ca 2ϩ -dependent glutamate release during ischemia (Bezzi and Volterra, 2001) . In apparent contrast with these results by Marcoli et al. (2004) , Hegstad et al. (1996) found glutamate (as well as GABA and glycine) efflux from ischemic human cerebrocortical slices to be independent of extracellular Ca 2ϩ . However, the Ca 2ϩ dependency was evaluated by these authors during static incubation and by adding Ca 2ϩ -free medium concomitantly with the ischemic insult, whereas Marcoli et al. (2004) worked under superfusion conditions and removed Ca 2ϩ before the ischemic insult. The Ca 2ϩ dependence and the tetrodotoxin sensitivity of glutamate efflux, together with the return to basal levels after a few minutes of reperfusion, are consistent with a relatively good viability of glutamatergic axon terminals in human brain exposed to moderate ischemic FUNCTIONAL PHARMACOLOGY IN HUMAN BRAIN insult. It is known that extracellular K ϩ concentrations can rise up to 60 mM during brain ischemia (Szatkowski and Attwell, 1994) , which is compatible with glutamate release occurring in part by depolarization-evoked opening of VSCCs and consequent vesicular exocytosis; indeed, in human cerebrocortical tissues, the efflux of glutamate, aspartate, GABA, and glycine evoked by K ϩ depolarization was found to be largely dependent on external Ca 2ϩ (Hegstad et al., 1996; Bonanno et al., 1997) .
Interestingly, the glutamate efflux from human cerebrocortical slices during oxygen and glucose deprivation (Marcoli et al., 2004) exhibited close similarities, as far as dependence on external Ca 2ϩ and sensitivity to tetrodotoxin are concerned, with the glutamate efflux from rat cerebrocortical slices previously observed under the same experimental conditions (Marcoli et al., 2003) , suggesting that rat ischemic cerebrocortical slices represent a useful experimental model to assess drug effects on glutamate efflux ultimately transferable to humans. Of note, it was observed that a longer oxygen/glucose deprivation is necessary to evoke glutamate release from human with respect to rat slices, consistent with an apparent greater resistance of the human tissue to ischemia (Jiang and Haddad, 1992) .
2. Glutamate Release and Adenosine A 2A Receptors. If a consistent portion of the glutamate efflux caused by ischemia in human brain occurs by exocytosis, it should be possible to prevent it by activating presynaptic receptors, which can regulate the Ca 2ϩ -dependent component of the depolarization-evoked neurotransmitter release from axon terminals (Langer, 1993; Levi and Raiteri, 1993) .
The ischemia-evoked glutamate efflux from human cerebrocortex slices was significantly reduced by blocking adenosine receptors of the A 2A subtype with the selective compound SCH58261 (Zocchi et al., 1996) . One interpretation is that glutamate release-enhancing A 2A receptors exist in human cerebral cortex, the activation of which by endogenously released adenosine participates in the glutamate efflux occurring during ischemia. Accordingly, presynaptic release-enhancing A 2A receptors had been found on rat cerebrocortex glutamatergic synaptosomes (Marchi et al., 2002a) . Blockade of A 2A receptors was ineffective on the release of glutamate occurring in human cerebrocortical slices superfused in Ca 2ϩ -free medium, which strengthens the view that adenosine endogenously released during ischemia activates exocytotic release-enhancing A 2A receptors present on glutamatergic terminals. Consistent with the idea that A 2A receptor block could prevent potentially detrimental activation of A 2A receptors, ischemic damage was reported to be reduced by A 2A receptor antagonists in rats (Phillis, 1995; Monopoli et al., 1998; von Lubitz, 1999) or in A 2A receptor knockout mice (Chen et al., 1999 ).
Glutamate Release and 5-Hydroxytryptamine Receptors.
In human cerebral cortex, 5-HT seems to be an important regulator of glutamatergic transmission: the indoleamine was found to reduce the depolarizationevoked glutamate release (Maura et al., 1998) and the production of NO and cyclic GMP due to activation of ionotropic glutamate receptors (Maura et al., 2000) through multiple pre-and postsynaptic 5-HT receptors (see Fig. 1 ).
When 5-HT was added concomitantly with oxygen/ glucose-deprived solution to human cerebrocortical slices in superfusion, the ischemia-evoked efflux of previously accumulated [ 3 H]D-aspartate or of endogenous glutamate was significantly reduced by ϳ60%. The effect of 5-HT was in part mimicked by the 5-HT 1A receptor agonist 8-OH-DPAT, which prevented the ischemiaprovoked glutamate overflow by ϳ40% (Marcoli et al., 2004) . Agonists at the 5-HT 1A receptor had been reported to prevent glutamate release in in vivo and in vitro rat models of ischemia (Mauler et al., 2001; Dawson et al., 2002) . In slices of human cerebral cortex, postsynaptic 5-HT 1A receptors were found to hyperpolarize glutamatergic pyramidal neuron (Newberry et al., 1999) and to inhibit the NO synthase/guanylyl cyclase pathway linked to NMDA glutamate receptor activation (Maura et al., 2000) . It would be interesting to explore in future studies receptor-receptor interactions between 5-HT and NMDA receptors possibly colocalized on glutamatergic neurons. In fact, hyperpolarizing 5-HT 1A receptors controlling NMDA-dependent excitation might directly protect neurons against excitotoxicity during and after ischemia, consistent with observations in in vitro and in vivo animal models (Azmitia, 2001; Harkany et al., 2001 ).
The 5-HT 1A agonist 8-OH-DPAT mimicked only in part the effect of 5-HT, suggesting the involvement of additional mechanisms. Inhibition by 5-HT of the ischemia-evoked glutamate efflux could also involve activation of release-inhibitory h5-HT 1D heteroreceptors previously found to be sited on human cerebrocortical glutamatergic axon terminals (Maura et al., 1998) . Thus, it is reasonable to propose that presynaptic 5-HT 1D and postsynaptic 5-HT 1A receptors cooperate in reducing glutamatergic transmission when human cerebral cortex slices are exposed to ischemic insults. To conclude, selective 5-HT ligands may deserve to be considered in a multipharmacological approach to neuroprotection in brain ischemia.
B. Glutamatergic Transmission following Brain Injury:
In Vivo Microdialysis Studies Persson et al. (1996) measured glutamate in dialysate samples collected for periods ranging from 6 to 11 days after ictus in 10 patients with subarachnoid hemorrhage. The data were matched with tomography findings, clinical course, and outcome. According to the authors, the correlation between the dialysate levels of 184 RAITERI glutamate and outcome supports the concept of glutamate receptor overactivation in acute human brain injury. Bullock et al. (1998) investigated the role of glutamatergic transmission in patients who suffered severe traumatic head injury. Excessive amounts of excitatory amino acids (EAAs) in the extracellular space may lead to neurotoxicity and cell death. The authors placed a microdialysis probe into the grey matter for 4 days and monitored the levels of glutamate/aspartate in the dialysate. The levels of EAAs were dramatically increased in several patients; secondary ischemic brain injury and poor outcome were strongly correlated with high EAA levels. Thus, according to Bullock et al. (1998) , these patients may be the best candidates for treatment with glutamate antagonists in the future.
Extracellular glutamate was monitored for 9 days in 17 patients following severe traumatic brain injury (Vespa et al., 1998) . The glutamate levels were particularly increased on postinjury day 3. Transient elevations of dialysate glutamate were seen each day, in conjunction with seizure activity, in a number of patients. In many seizure-free patients, the increase in extracellular glutamate occurred when cerebral perfusion pressure was Ͻ70 mm Hg.
More recently, the amino acid content of microdialysis samples from nine children with severe head injuries was examined (Richards et al., 2003) . Although the interpretation of changes in extracellular glutamate levels measured by microdialysis is complicated by many factors, well discussed by the authors, a link between high dialysate glutamate and less favorable outcome seems established both in adults (Bullock et al., 1998) and in children. Interestingly, the relationship between levels of glutamate and glutamine seems to have good prognostic value. In particular, an increased extracellular glutamine/glutamate ratio is associated with more favorable outcome so that estimation of this ratio may have some prognostic value in head trauma.
XIV. Effects of HIV-1 Proteins
The clinical manifestations of AIDS often include neurological and neuropsychiatric disturbances known as the AIDS dementia complex . The origins of the motor, cognitive, and behavioral impairments accompanying HIV-1 infection, may be present in ϳ30% of adult patients but in ϳ70% of children, are poorly understood. Because neurons can rarely, if ever, be infected by the virus, it is hypothesized that indirect mechanisms are primarily involved in the neuronal deficits and in the neurotoxic events that often occur during AIDS infection (Kaul and Lipton, 1999; Valle et al., 2000; Bezzi et al., 2001; Kaul et al., 2001; Mollace et al., 2001) , although direct effects of HIV-1 proteins have been reported as well (see below).
The occurrence of neurotoxic events is sustained by postmortem histological observations made in cerebral tissue from HIV-1-positive patients, in whom loss of neurons has clearly been described previously (Fox et al., 1997; Masliah et al., 1997; Everall et al., 1999) . These dramatic effects may, however, not be necessary to explain the above-mentioned neuropsychiatric deficits; in fact, relatively subtle changes in central neurotransmission induced by HIV-1 proteins might be at the basis of various functional impairments.
A. Activation of Glutamate N-Methyl-D-aspartate Receptors by gp120
In the last decade, evidence has been provided suggesting that the HIV-1 envelope protein gp120 could directly influence central neuronal functions, causing changes in neurotransmitter release or affecting receptor-mediated mechanisms which may not be necessarily related to neuronal damage, but may underlie the cognitive and behavioral impairments characteristic of the AIDS dementia complex.
To investigate whether gp120 can directly affect receptor function in the human brain, the effect of the coat protein on the release of NE evoked by NMDA receptor activation in human cerebrocortical nerve ending preparations was studied (Pittaluga et al., 1996) . This system was chosen because 1) NMDA receptors had been reported to be major agents in the neurotoxic effects of gp120 in various experimental animal models, very often in cell cultures (Brennemann et al., 1988; Dreyer et al., 1990; Mü ller et al., 1992; Dawson et al., 1993; Savio and Levi, 1993; Kaul et al., 2001) , 2) NMDA receptors play a critical role in the processes of learning and memory (Collingridge and Bliss, 1987) , 3) NE also is positively involved in cognition, particularly in attentive activities (Cahill et al., 1994; Aston-Jones, 2002; Berridge and Waterhouse, 2003) , and 4) the human cerebral cortex was reported to contain NMDA receptors, the activation of which mediates increase of NE release (Fink et al., 1992a) .
When added during superfusion to human cerebrocortical synaptosomes prelabeled with [ The release elicited by NMDA plus gp120 was prevented by 7-Cl-kynurenate, an antagonist at the glycine site of the NMDA receptor and by the open channel blockers dizocilpine and memantine. Interestingly, the effect of gp120 was retained by its peptide fragment termed the V3 loop. Finally, gp120 was able to reverse and surmount the antagonism by 7-Cl-kynurenate of the NMDA-evoked [ 3 H]NE release (Pittaluga et al., 1996) .
These results show that a binding site for gp120 exists on the axon terminals of noradrenergic neurons in the human cerebral cortex. By acting at this site, probably FUNCTIONAL PHARMACOLOGY IN HUMAN BRAIN through the V3 loop, the HIV-1 coat protein would facilitate the NE-releasing activity of endogenous NMDA receptor agonists (glutamate, aspartate, and quinolinic acid). This site of binding for gp120 seems to be the glycine site of NMDA receptors where gp120 acts as a "false" glycinergic coagonist of glutamate. Pathologically relevant is the observation that gp120 (or V3) is 3 to 4 orders of magnitude more potent than the natural ligand glycine. The potency of these foreign agonists, together with their likely prolonged persistence at the NMDA receptors, might lead to serious impairments of NMDA receptor-mediated neurotransmission. In fact, only glycine, but not gp120 (or V3), is expected to be released phasically onto NMDA receptors and to be efficiently removed by reuptake. An abnormal and persistent reinforcement of the glutamate-dependent NE release due to the presence of gp120 (or its V3 loop) in the biophase of NMDA receptors might lead to unbalances in the processes underlying learning and memory, thus contributing to the cognitive deficits characteristic of AIDS dementia. It may be worth a reminder that intracerebral administration of gp120 in rats was reported to cause learning impairment (Glowa et al., 1992) in absence of signs of degeneration (Bagetta et al., 1994) .
The finding that memantine was able to prevent the gp120 potentiation of the NMDA-evoked effect is of interest. Memantine is a low-affinity, uncompetitive, open-channel blocker of the NMDA receptor, which was reported not to substantially affect normal synaptic activity but to prevent excessive NMDA activity (Lipton and Chen, 2004) . Memantine has recently been introduced for the treatment of Alzheimer's disease, but additional clinical studies of memantine for other forms of dementia, including the AIDS dementia complex, are currently underway.
Results almost identical to those obtained with human cerebral cortex nerve endings were obtained when gp120 and its V3 loop were studied using rat nerve ending preparations (Pittaluga and Raiteri, 1994; Pattarini et al., 1998) , suggesting that the NMDA-evoked release of NE from rat nerve endings represents a convenient model to investigate the mechanistic aspects of the action of gp120 and its peptide fragments on NMDA receptors and to test compounds potentially useful in the treatment of AIDS dementia.
B. Activation of Glutamate Metabotropic Receptors by Tat
Increasing attention has been focused on Tat, a nonstructural viral protein known to be produced and actively released by HIV-1-infected cells (Ensoli et al., 1993) . Tat has been detected in the brain of animals with viral encephalitis and its encoding mRNA has been found in the CNS of HIV-1-infected patients exhibiting AIDS dementia symptoms (Hudson et al., 2000; Valle et al., 2000) .
Tat can apparently induce neurological/neuropsychiatric impairments and neurotoxicity because it was shown both to excite and kill human and rodent cerebrocortical neurons (Nath et al., 1996; Kruman et al., 1998) by mechanisms involving neuronal Ca 2ϩ homeostasis (Haughey et al., 1999 (Haughey et al., , 2001 . The protein binds to and depolarizes neuronal membranes (Sabatier et al., 1991) , allowing increases in cytosolic Ca 2ϩ through receptor-operated channels and mobilization from inositol trisphosphate-sensitive internal stores (Nath et al., 1996; Haughey et al., 1999 Haughey et al., , 2001 .
We investigated whether Tat can affect neurotransmission in human brain by modulating transmitter release from fresh human cerebrocortical nerve ending preparations (Feligioni et al., 2003) . Experiments with corresponding preparations from rat brain were run in parallel. Tat was found to selectively enhance the release of ACh; the protein was in fact unable to affect the basal release of endogenous glutamate, aspartate, GABA, serine, and NE but, added at 1 to 3 nM, it evoked release of [ 3 H]ACh from human and rat cerebrocortical synaptosomes prelabeled with [ 3 H]choline. As illustrated schematically in Fig. 4 , in human nerve endings, the Tat-evoked release of ACh depends on activation of group I metabotropic glutamate receptors, and mobilization of Ca 2ϩ from inositol trisphosphate-sensitive intraterminal stores. In contrast, in rat nerve endings, the Tat-evoked ACh release seems to involve mobilization of Ca 2ϩ from ryanodine-sensitive internal stores triggered by the binding of Tat to an as yet unidentified "receptor" on cholinergic neurons the activation of which leads to cyclic adenosine diphosphoribose production (Feligioni et al., 2003) .
In conclusion, Tat can evoke release of ACh from human and rat cerebrocortex cholinergic axon terminals with remarkable neuronal selectivity. The mechanism involved in the release from human terminals differs strikingly from that in rodent terminals. Tat binds to different recognition sites on human versus rat cholinergic terminals, a view that is also supported by the finding that the releasing effect of Tat in human terminals is mimicked by peptide fragments different from those mimicking it in rat terminals. Therefore, differently from the case of gp120, the rodent model should be used with great caution when Tat effects on neurotransmission are studied.
The pathophysiological significance of the Tat effects on ACh release is presently unknown. In any case, once present in the brain extracellular fluid, Tat may not be easily inactivated and may therefore, as the intact protein or in the form of active peptide fragments, provoke release of ACh outside of the physiological range and with abnormal kinetic characteristics, potentially contributing to the behavioral disturbances occurring in AIDS dementia.
RAITERI
XV. Parkinson's Disease: In Vivo Microdialysis Studies
Microdialysis measurements in the brain of patients with Parkinson's disease (PD) were performed for the first time in 1989 (Meyerson et al., 1990 ) during neurosurgical thalamotomy to relieve tremor. This was possible as the microdialysis probes were introduced through the same trajectory as the lesioning electrode, thus causing no additional damage to the brain. The main goal was to test the reliability of the microdialysis technique for biochemical characterization of the target area in the human brain during a routine operation. In this study, dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 5-hydroxyindoleacetic acid, hypoxanthine, inosine, guanosine, adenosine, GABA, taurine, aspartate, and glutamate were measured in the dialysates from the thalamus. The results showed that the technique was safe, no additional damage was observed and consistent and levels of reproducible analytes could be measured, following 20 to 30 min of stabilization.
Later on, this technique was also used during neurosurgery of patients with PD for implantation of electrodes for deep brain stimulation (DBS) in the internal globus pallidus (GPi) and subthalamic nucleus (STN), after prolonged therapy washout (Fedele et al., 2001a, b) . In these studies, the extracellular levels of aspartate, glutamate, glycine, and GABA in the external globus pallidus (GPe), GPi, and STN were measured before (off-state) and after (on-state) perioperative administration of a clinically effective dose of apomorphine. In the off-state, it has been found that GABA basal levels in the GPi were significantly higher than those measured in the GPe and STN. Considering the current view on basal ganglia pathophysiology, the higher GABA levels in the GPi should not be caused by the degenerative pathology, as both GABAergic pathways reaching this brain region (the direct pathway from the putamen and the indirect pathway via collaterals of the GPe fibers directed to the STN) are supposed to be less active in off-state PD patients (Albin et al., 1989; De Long, 1990; Lang and Lozano, 1998a,b) . Therefore, this finding indicates that the GPi receives more GABAergic inputs than the other basal ganglia nuclei and could represent a biochemical marker for GPi target identification in PD surgery (Fedele et al., 2001a,b) . Unexpectedly, administration of apomorphine failed to alter amino acids levels in all the brain structures investigated, despite the significant decrease of GPi and STN firings, measured by electrophysiological recordings and the clear-cut amelioration of clinical symptoms, suggesting that the acute effects of the dopaminergic therapy are not due to modulation of neuroactive amino acid release. However, as authors themselves acknowledge, such negative findings may be due to limitations of the microdialysis technique that can fail to detect physiologically relevant synaptic events if they do not sufficiently leak out of the synaptic cleft into the extracellular milieu. Moreover, microdialysis data from laboratory animals have shown that extracellular basal levels of amino acids, especially glutamate, might originate from metabolic pools, which can obscure possible changes in the levels of neuronal nature (Timmerman and Westerink, 1997) .
Recently, to unravel the mechanisms underlying the beneficial effects of DBS of the STN (STN-DBS), the same research group has investigated the effects of this type of stimulation on the extracellular levels of cGMP in the GPi of PD patients (Stefani et al., 2005) . Cyclic GMP has been monitored as a marker of glutamatergic transmission, given the possible limitations of the microdialysis technique in measuring variations of extracellular glutamate mentioned above. As a matter of fact, it has been extensively documented that the production FIG. 4 . Effects of the HIV-1 protein Tat on the release of ACh from human and rat neocortical cholinergic nerve endings. In human neocortex, Tat activates glutamate group I metabotropic receptors (mGluRI) on ACh terminals leading to inositol trisphosphate (IP 3 ) production, IP 3 receptor (IP 3 R) activation, mobilization of Ca 2ϩ from the endoplasmic reticulum (ER), and vesicular ACh release. In rat neocortex cholinergic terminals Tat binds to an unidentified receptor whose activation leads to ACh release. This release also is dependent on intraterminal Ca 2ϩ , but this is mobilized by ryanodine receptor (RYR) activation via the endogenous agonist cADPR.
FUNCTIONAL PHARMACOLOGY IN HUMAN BRAIN of this cyclic nucleotide is particularly linked to glutamatergic neurotransmission, via activation of NO/synthase, and can be measured in vivo by microdialysis in different brain regions of rodents (Vallebuona and Raiteri, 1994) [see , Pepicelli et al. (2004) , and references therein for reviews]. Authors found that extracellular cyclic GMP basal levels were significantly augmented during clinically effective STN-DBS, indicating an increased activity of the STN-GPi glutamatergic pathway. This result is at variance with the initial hypothesis suggesting that the beneficial effects of STN-DBS were due to the high frequency-mediated inactivation of STN cells (Benazzouz et al., 1995; Filali et al., 2004; Welter et al., 2004) . However, it has also been shown that STN cells can fire at peculiarly high frequency rates, either spontaneously or during passive movement (Levy et al., 2001; Stefani et al., 2002) . Moreover, STN stimulation leads to the increase in blood oxygenation level-dependent signals and blood flow in ipsilateral basal ganglia workstations, as assessed by functional magnetic resonance imaging and positron emission tomography techniques (Jech et al., 2001; Hershey et al., 2003) , suggesting stimulation, and not inhibition, of GPi activity. Finally, GPi firing activity is increased during STN-DBS in a primate model of PD, demonstrating that the stimulation can reinforce and synchronize, but not suppress, the glutamatergic driving force from STN (Hashimoto et al., 2003) . However, all these data conflict with the well-established concept that STN-DBS-induced relief of PD symptoms are mediated by disinhibition of the thalamocortical pathway, which, in turn, should be accomplished by a decrease and not increase in GPi activity. Therefore, additional studies will be necessary to untangle this paradox.
XVI. Conclusions
This article is a comprehensive review of the work carried out in the last decade on human brain functional proteins, particularly neurotransmitter receptors. The literature available on the topic shows that the large majority of the studies have been performed with fresh tissue samples obtained from neurosurgery. It seems clear that frozen brain samples from autopsies, certainly useful in experimental approaches such as radioligand binding, lend themselves poorly to studies aimed to understand the function of receptors, transporters, ion channels, and enzymes. Surprisingly, a large proportion of the reports deal with neurotransmitter release and release-regulating receptors, indicating that the physiology and pharmacology of these fundamental neuronal properties can be conveniently investigated in neurosurgically derived human brain tissue samples. Relatively less abundant are the reports regarding electrophysiological works; these were generally performed using slices of epileptogenic regions and almost exclusively focussed on transmitter amino acid receptors. Some publications describe changes in neurotransmitter amino acids and second messengers monitored during microdialysis in epileptic or parkinsonian patients undergoing neurosurgery. Besides the obvious importance of the information one can obtain when working with human brain, this approach seems unique for a number of reasons. Since the availability of fresh human tissue specimens is rare, it is critical to identify animal species in which functionally corresponding receptors exhibit pharmacological profiles identical or very similar to those in humans, so that they can be used as models in preclinical pharmacology. Moreover, heterologous expression of human receptors/transporters may not represent substantial alternatives to native proteins whose function and pharmacology is dependent on a number of interactions with agents that may exclusively be present in their natural environment.
